CA1223831A
(en)
|
1982-06-23 |
1987-07-07 |
Dean Engelhardt |
Modified nucleotides, methods of preparing and utilizing and compositions containing the same
|
US6399754B1
(en)
|
1991-12-24 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides
|
US5872232A
(en)
*
|
1990-01-11 |
1999-02-16 |
Isis Pharmaceuticals Inc. |
2'-O-modified oligonucleotides
|
US5859221A
(en)
*
|
1990-01-11 |
1999-01-12 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
US6005087A
(en)
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
US5965722A
(en)
*
|
1991-05-21 |
1999-10-12 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
|
US5747253A
(en)
*
|
1991-08-23 |
1998-05-05 |
Isis Pharmaceuticals, Inc. |
Combinatorial oligomer immunoabsorbant screening assay for transcription factors and other biomolecule binding
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
EP1256589A3
(de)
*
|
1991-11-26 |
2003-09-17 |
Isis Pharmaceuticals, Inc. |
Oligomere, die modifizierte PyrimIdine enthalten
|
US6235887B1
(en)
|
1991-11-26 |
2001-05-22 |
Isis Pharmaceuticals, Inc. |
Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
|
TW393513B
(en)
*
|
1991-11-26 |
2000-06-11 |
Isis Pharmaceuticals Inc |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
WO1993012135A1
(en)
|
1991-12-12 |
1993-06-24 |
Gilead Sciences, Inc. |
Nuclease stable and binding competent oligomers and methods for their use
|
FR2688003B1
(fr)
*
|
1992-02-28 |
1995-06-30 |
Univ Limoges |
Derives de nucleosides, leur preparation et leurs applications biologiques.
|
US6291438B1
(en)
|
1993-02-24 |
2001-09-18 |
Jui H. Wang |
Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
|
DE69433036T2
(de)
|
1993-09-03 |
2004-05-27 |
Isis Pharmaceuticals, Inc., Carlsbad |
Aminoderivatisierte nukleoside und oligonukleoside
|
US6376178B1
(en)
*
|
1993-09-03 |
2002-04-23 |
Duke University |
Method of nucleic acid sequencing
|
DE4415370A1
(de)
*
|
1994-05-02 |
1995-11-09 |
Hoechst Ag |
Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
|
DE4438918A1
(de)
*
|
1994-11-04 |
1996-05-09 |
Hoechst Ag |
Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
|
US6150510A
(en)
|
1995-11-06 |
2000-11-21 |
Aventis Pharma Deutschland Gmbh |
Modified oligonucleotides, their preparation and their use
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
WO1996040726A1
(en)
|
1995-06-07 |
1996-12-19 |
Genta Incorporated |
Novel carbamate-based cationic lipids
|
US6160109A
(en)
*
|
1995-10-20 |
2000-12-12 |
Isis Pharmaceuticals, Inc. |
Preparation of phosphorothioate and boranophosphate oligomers
|
US6476216B1
(en)
|
1995-10-20 |
2002-11-05 |
Mcgill University |
Preparation of phosphorothioate oligomers
|
US5734041A
(en)
*
|
1995-10-20 |
1998-03-31 |
Mcgill University |
Preparation of chiral phosphorothioate oligomers
|
US20010018514A1
(en)
*
|
1998-07-31 |
2001-08-30 |
Mcgall Glenn H. |
Nucleic acid labeling compounds
|
US7282327B2
(en)
|
1996-01-23 |
2007-10-16 |
Affymetrix, Inc. |
Nucleic acid labeling compounds
|
US6864059B2
(en)
|
1996-01-23 |
2005-03-08 |
Affymetrix, Inc. |
Biotin containing C-glycoside nucleic acid labeling compounds
|
US7423143B2
(en)
|
1996-01-23 |
2008-09-09 |
Affymetrix. Inc. |
Nucleic acid labeling compounds
|
US6965020B2
(en)
|
1996-01-23 |
2005-11-15 |
Affymetrix, Inc. |
Nucleic acid labeling compounds
|
US7291463B2
(en)
|
1996-01-23 |
2007-11-06 |
Affymetrix, Inc. |
Nucleic acid labeling compounds
|
AU2733697A
(en)
*
|
1996-04-17 |
1997-11-07 |
Aronex Pharmaceuticals, Inc. |
Antisense inhibitors of vascular endothelial growth factor (vegf/vpf) expression
|
US5856099A
(en)
*
|
1996-05-21 |
1999-01-05 |
Isis Pharmaceuticals, Inc. |
Antisense compositions and methods for modulating type I interleukin-1 receptor expression
|
US9096636B2
(en)
*
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US20040161777A1
(en)
*
|
1996-06-06 |
2004-08-19 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US20040203024A1
(en)
*
|
1996-06-06 |
2004-10-14 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
US20040266706A1
(en)
*
|
2002-11-05 |
2004-12-30 |
Muthiah Manoharan |
Cross-linked oligomeric compounds and their use in gene modulation
|
US20050042647A1
(en)
*
|
1996-06-06 |
2005-02-24 |
Baker Brenda F. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
US20040147022A1
(en)
*
|
1996-06-06 |
2004-07-29 |
Baker Brenda F. |
2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
US20040171028A1
(en)
*
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
US20030044941A1
(en)
|
1996-06-06 |
2003-03-06 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20050053976A1
(en)
*
|
1996-06-06 |
2005-03-10 |
Baker Brenda F. |
Chimeric oligomeric compounds and their use in gene modulation
|
US6093816A
(en)
|
1996-06-27 |
2000-07-25 |
Isis Pharmaceuticals, Inc. |
Cationic lipids
|
US7070925B1
(en)
|
1996-07-16 |
2006-07-04 |
Gen-Probe Incorporated |
Method for determining the presence of an RNA analyte in a sample using a modified oligonucleotide probe
|
CA2260749A1
(en)
*
|
1996-07-16 |
1998-01-22 |
Gen-Probe Incorporated |
Methods for detecting rna analytes using modified probes
|
US6576752B1
(en)
|
1997-02-14 |
2003-06-10 |
Isis Pharmaceuticals, Inc. |
Aminooxy functionalized oligomers
|
US6127533A
(en)
|
1997-02-14 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
2'-O-aminooxy-modified oligonucleotides
|
US6172209B1
(en)
|
1997-02-14 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Aminooxy-modified oligonucleotides and methods for making same
|
US6034135A
(en)
*
|
1997-03-06 |
2000-03-07 |
Promega Biosciences, Inc. |
Dimeric cationic lipids
|
US5877220A
(en)
*
|
1997-03-06 |
1999-03-02 |
Genta, Incorporated |
Amide-based oligomeric cationic lipids
|
CA2294988C
(en)
|
1997-07-01 |
2015-11-24 |
Isis Pharmaceuticals Inc. |
Compositions and methods for the delivery of oligonucleotides via the alimentary canal
|
US6028183A
(en)
*
|
1997-11-07 |
2000-02-22 |
Gilead Sciences, Inc. |
Pyrimidine derivatives and oligonucleotides containing same
|
US6007992A
(en)
*
|
1997-11-10 |
1999-12-28 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
US20040186071A1
(en)
*
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
US7321828B2
(en)
*
|
1998-04-13 |
2008-01-22 |
Isis Pharmaceuticals, Inc. |
System of components for preparing oligonucleotides
|
CA2329130A1
(en)
*
|
1998-05-21 |
1999-11-25 |
Isis Pharmaceuticals Inc. |
Compositions and methods for non-parenteral delivery of oligonucleotides
|
JP2002515514A
(ja)
*
|
1998-05-21 |
2002-05-28 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
オリゴヌクレオチドの局所送逹のための組成物及び方法
|
US6562798B1
(en)
*
|
1998-06-05 |
2003-05-13 |
Dynavax Technologies Corp. |
Immunostimulatory oligonucleotides with modified bases and methods of use thereof
|
US6043352A
(en)
|
1998-08-07 |
2000-03-28 |
Isis Pharmaceuticals, Inc. |
2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
|
US6673912B1
(en)
|
1998-08-07 |
2004-01-06 |
Isis Pharmaceuticals, Inc. |
2′-O-aminoethyloxyethyl-modified oligonucleotides
|
US6225293B1
(en)
|
1998-09-02 |
2001-05-01 |
Isis Pharmaceuticals, Inc. |
Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
US6492111B1
(en)
|
1998-11-25 |
2002-12-10 |
Isis Pharmaceuticals, Inc. |
In situ binary synthesis of biologically effective molecules
|
US6692959B2
(en)
*
|
1998-11-25 |
2004-02-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of IL-1 receptor-associated kinase-4 expression
|
US6300320B1
(en)
|
1999-01-05 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Modulation of c-jun using inhibitors of protein kinase C
|
US6403779B1
(en)
|
1999-01-08 |
2002-06-11 |
Isis Pharmaceuticals, Inc. |
Regioselective synthesis of 2′-O-modified nucleosides
|
US6127124A
(en)
|
1999-01-20 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
Fluorescence based nuclease assay
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
US6147200A
(en)
*
|
1999-08-19 |
2000-11-14 |
Isis Pharmaceuticals, Inc. |
2'-O-acetamido modified monomers and oligomers
|
US6277982B1
(en)
|
1999-08-20 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Alkylation of alcohols, amines, thiols and their derivatives by cyclic sulfate intermediates
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20030176385A1
(en)
*
|
2000-02-15 |
2003-09-18 |
Jingfang Ju |
Antisense modulation of protein expression
|
US7115738B2
(en)
|
2000-03-14 |
2006-10-03 |
Active Motif |
Hydroxyproline/phosphono oligonucleotide analogues, methods of synthesis and methods of use
|
US6962906B2
(en)
|
2000-03-14 |
2005-11-08 |
Active Motif |
Oligonucleotide analogues, methods of synthesis and methods of use
|
WO2001085751A1
(en)
*
|
2000-05-09 |
2001-11-15 |
Reliable Biopharmaceutical, Inc. |
Polymeric compounds useful as prodrugs
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
US20060166227A1
(en)
*
|
2000-06-20 |
2006-07-27 |
Stephen Kingsmore |
Protein expression profiling
|
US6323009B1
(en)
*
|
2000-06-28 |
2001-11-27 |
Molecular Staging, Inc. |
Multiply-primed amplification of nucleic acid sequences
|
US8568766B2
(en)
*
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
EP2336166A1
(de)
|
2000-10-12 |
2011-06-22 |
University Of Rochester |
Zusammensetzungen die die Proliferation von Krebszellen hemmen
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
WO2002070535A1
(en)
*
|
2001-03-01 |
2002-09-12 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of recql5 expression
|
US6573051B2
(en)
*
|
2001-03-09 |
2003-06-03 |
Molecular Staging, Inc. |
Open circle probes with intramolecular stem structures
|
AU2002258502A1
(en)
|
2001-03-12 |
2002-09-24 |
Affymetrix, Inc. |
Nucleic acid labeling compounds
|
DE10120798B4
(de)
*
|
2001-04-27 |
2005-12-29 |
Genovoxx Gmbh |
Verfahren zur Bestimmung der Genexpression
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
CA2633595A1
(en)
|
2001-06-20 |
2003-01-03 |
Genentech, Inc. |
Antibodies against tumor-associated antigenic target (tat) polypeptides
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
EP2221376B1
(de)
|
2001-06-21 |
2012-11-21 |
Isis Pharmaceuticals, Inc. |
Antisense-Modulation von Superoxid-Dismutase 1, Expression in Lösung
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
ATE486092T1
(de)
|
2001-09-18 |
2010-11-15 |
Genentech Inc |
Zusammensetzungen und verfahren für die diagnose von tumoren
|
NZ566396A
(en)
|
2001-10-09 |
2009-07-31 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expressions
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
DE10159904A1
(de)
*
|
2001-12-06 |
2003-07-03 |
Adnagen Ag |
Oligonukleotidanordnung, Verfahren zum Nukleotidnachweis sowie Vorrichtung hierfür
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
EP2067472A1
(de)
|
2002-01-02 |
2009-06-10 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
US20030166282A1
(en)
*
|
2002-02-01 |
2003-09-04 |
David Brown |
High potency siRNAS for reducing the expression of target genes
|
ATE529512T1
(de)
|
2002-02-01 |
2011-11-15 |
Life Technologies Corp |
Doppelsträngige oligonukleotide
|
US7553619B2
(en)
*
|
2002-02-08 |
2009-06-30 |
Qiagen Gmbh |
Detection method using dissociated rolling circle amplification
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
US7169916B2
(en)
*
|
2002-04-01 |
2007-01-30 |
Isis Pharmaceuticals, Inc. |
Chloral-free DCA in oligonucleotide synthesis
|
CA2481507A1
(en)
|
2002-04-16 |
2003-10-30 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7176181B2
(en)
*
|
2002-05-21 |
2007-02-13 |
Yeda Research And Development Co. Ltd. |
Compositions and methods of using galectin-8 as an inhibitor of tumor cell growth
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
US20100075423A1
(en)
*
|
2002-06-12 |
2010-03-25 |
Life Technologies Corporation |
Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
|
US20040248094A1
(en)
*
|
2002-06-12 |
2004-12-09 |
Ford Lance P. |
Methods and compositions relating to labeled RNA molecules that reduce gene expression
|
US20040092470A1
(en)
*
|
2002-06-18 |
2004-05-13 |
Leonard Sherry A. |
Dry powder oligonucleotide formualtion, preparation and its uses
|
EP2116604A1
(de)
|
2002-08-05 |
2009-11-11 |
University of Rochester |
Proteinumwandlungsdomäne / Deaminasechimäre Proteine, zugehörige Verbindungen und Verwendungen davon
|
US20040029275A1
(en)
*
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
JP2006500030A
(ja)
*
|
2002-09-20 |
2006-01-05 |
イェール ユニバーシティ |
リボスイッチ、その使用方法、ならびにリボスイッチとともに用いるための組成物
|
EP1549767A4
(de)
|
2002-09-26 |
2006-06-07 |
Amgen Inc |
Modulation der expression von forkhead-box o1a
|
AU2003304203A1
(en)
*
|
2002-10-29 |
2005-01-04 |
Pharmacia Corporation |
Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
|
US9150606B2
(en)
*
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
WO2004044138A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
AU2003290596B2
(en)
|
2002-11-05 |
2011-05-12 |
Isis Pharmaceuticals, Inc. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
JP4986109B2
(ja)
|
2002-11-13 |
2012-07-25 |
ジェンザイム・コーポレーション |
アポリポタンパク質b発現のアンチセンス調節
|
ES2417879T3
(es)
|
2002-11-13 |
2013-08-09 |
Genzyme Corporation |
Modulación antisentido de la expresión de la apolipoproteína B
|
ES2392511T3
(es)
|
2002-11-15 |
2012-12-11 |
Musc Foundation For Research Development |
Moduladores de complemento dianas sobre el receptor 2 de complemento
|
AU2003295576B2
(en)
*
|
2002-11-15 |
2011-03-17 |
Eisai, Inc. |
Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
|
CA2507044A1
(en)
|
2002-11-21 |
2004-06-10 |
Mary Lucero |
Purinergic modulation of smell
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
US20070021361A1
(en)
*
|
2002-12-04 |
2007-01-25 |
Shuster Samuel J |
Methods and materials for modulating trpm2
|
US20040121338A1
(en)
*
|
2002-12-19 |
2004-06-24 |
Alsmadi Osama A. |
Real-time detection of rolling circle amplification products
|
US9487823B2
(en)
|
2002-12-20 |
2016-11-08 |
Qiagen Gmbh |
Nucleic acid amplification
|
JP4886298B2
(ja)
|
2002-12-20 |
2012-02-29 |
キアゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング |
核酸増幅
|
WO2004072284A1
(en)
|
2003-02-11 |
2004-08-26 |
Antisense Therapeutics Ltd |
Modulation of insulin like growth factor i receptor expression
|
US7002006B2
(en)
*
|
2003-02-12 |
2006-02-21 |
Isis Pharmaceuticals, Inc. |
Protection of nucleosides
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US8110674B2
(en)
|
2003-03-07 |
2012-02-07 |
Alnylam Pharmaceuticals, Inc. |
Therapeutic compositions
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US8043834B2
(en)
|
2003-03-31 |
2011-10-25 |
Qiagen Gmbh |
Universal reagents for rolling circle amplification and methods of use
|
US20040198640A1
(en)
*
|
2003-04-02 |
2004-10-07 |
Dharmacon, Inc. |
Stabilized polynucleotides for use in RNA interference
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
EP2666858A1
(de)
|
2003-04-17 |
2013-11-27 |
Alnylam Pharmaceuticals Inc. |
Modifizierte iRNA-Wirkstoffe
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
WO2004108081A2
(en)
*
|
2003-06-02 |
2004-12-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide synthesis with alternative solvents
|
WO2005002507A2
(en)
|
2003-06-03 |
2005-01-13 |
Isis Pharmaceuticals, Inc. |
Modulation of survivin expression
|
DK2336317T3
(da)
|
2003-06-13 |
2019-12-16 |
Alnylam Europe Ag |
Dobbeltstrenget ribonukleinsyre med forøget effektivitet i en organisme
|
EP1636342A4
(de)
*
|
2003-06-20 |
2008-10-08 |
Isis Pharmaceuticals Inc |
Oligomere verbindungen zur verwendung bei der modulation von genen
|
US7683036B2
(en)
|
2003-07-31 |
2010-03-23 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
NZ592039A
(en)
|
2003-08-27 |
2013-03-28 |
Ophthotech Corp |
Combination therapy for the treatment of ocular neovascular disorders
|
US20050053981A1
(en)
*
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
EP1677822B1
(de)
*
|
2003-09-18 |
2014-04-23 |
Isis Pharmaceuticals, Inc. |
4'-thionucleoside und oligomere verbindungen
|
BRPI0413930A
(pt)
|
2003-09-18 |
2006-10-24 |
Isis Pharmaceuticals Inc |
composto oligomérico ou sal farmaceuticamente aceitável deste, composição farmacêutica ou veterinária, métodos para inibir a expressão de eif4e em uma célula, tecido ou órgão, para diminuir a proliferação de uma célula em que eif4e é expressado, e para prevenir ou tratar uma condição ou doença métodos para prevenir ou diminuir a angiogênese, e o crescimento de tumor em um paciente, oligonucleotìdeo de anti-sentido, composição farmacêutica ou veterinária, e, uso de um composto oligomérico ou sal farmaceuticamente aceitável deste
|
US7125945B2
(en)
|
2003-09-19 |
2006-10-24 |
Varian, Inc. |
Functionalized polymer for oligonucleotide purification
|
JP2007507430A
(ja)
|
2003-10-10 |
2007-03-29 |
メディテック リサーチ リミテッド |
疾患の治療におけるヒアルロナン合成および分解の調節法
|
US20050239733A1
(en)
*
|
2003-10-31 |
2005-10-27 |
Coley Pharmaceutical Gmbh |
Sequence requirements for inhibitory oligonucleotides
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
CA2546285C
(en)
|
2003-11-17 |
2015-12-29 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
JP2007520222A
(ja)
|
2004-01-20 |
2007-07-26 |
アイシス ファーマシューティカルズ インコーポレイテッド |
グルココルチコイドレセプター発現の調節
|
US8778900B2
(en)
*
|
2004-01-22 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP1 expression
|
US7468431B2
(en)
*
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
US20090280567A1
(en)
*
|
2004-02-06 |
2009-11-12 |
Dharmacon, Inc. |
Stabilized sirnas as transfection controls and silencing reagents
|
WO2005078094A2
(en)
*
|
2004-02-06 |
2005-08-25 |
Dharmacon, Inc. |
Stabilized rnas as transfection controls and silencing reagents
|
US8569474B2
(en)
*
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
US8790919B2
(en)
|
2004-03-15 |
2014-07-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of RNA by RNase H
|
KR101147147B1
(ko)
*
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
US20050244869A1
(en)
*
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
WO2005097817A2
(en)
|
2004-04-05 |
2005-10-20 |
Alnylam Pharmaceuticals, Inc. |
Process and reagents for oligonucleotide synthesis and purification
|
US20050260755A1
(en)
*
|
2004-04-06 |
2005-11-24 |
Isis Pharmaceuticals, Inc. |
Sequential delivery of oligomeric compounds
|
AU2005323437B2
(en)
|
2004-04-30 |
2011-10-06 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a C5-modified pyrimidine
|
CA2564251C
(en)
|
2004-05-21 |
2018-04-10 |
The Uab Research Foundation |
Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
|
WO2005118806A2
(en)
|
2004-05-28 |
2005-12-15 |
Ambion, Inc. |
METHODS AND COMPOSITIONS INVOLVING MicroRNA
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
EP1766052A4
(de)
*
|
2004-06-03 |
2009-12-16 |
Isis Pharmaceuticals Inc |
Chimärische oligomere zusammensetzungen mit gap
|
CA2568735A1
(en)
*
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
WO2006020768A2
(en)
|
2004-08-10 |
2006-02-23 |
Alnylam Pharmaceuticals, Inc. |
Chemically modified oligonucleotides
|
WO2006028967A2
(en)
*
|
2004-09-02 |
2006-03-16 |
Yale University |
Regulation of oncogenes by micrornas
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
TR201907874T4
(tr)
*
|
2004-09-23 |
2019-06-21 |
Arc Medical Devices Inc |
Düşük sülfat fukanlar kullanarak fibröz yapışmaları ya da inflamatuar hastalıkları inhibe etmeye yönelik farmasötik kompozisyonlar ve yöntemler.
|
CA2857881A1
(en)
|
2004-11-12 |
2006-12-28 |
Asuragen, Inc. |
Methods and compositions involving mirna and mirna inhibitor molecules
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
US7935811B2
(en)
*
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
US7923206B2
(en)
*
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Method of determining a cellular response to a biological agent
|
AU2006223498A1
(en)
|
2005-03-10 |
2006-09-21 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
US7476733B2
(en)
*
|
2005-03-25 |
2009-01-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
|
WO2006110314A2
(en)
|
2005-03-25 |
2006-10-19 |
Ambion, Inc. |
Methods and compositions for depleting abundant rna transcripts
|
US20060223777A1
(en)
*
|
2005-03-29 |
2006-10-05 |
Dharmacon, Inc. |
Highly functional short hairpin RNA
|
EP1863908B1
(de)
*
|
2005-04-01 |
2010-11-17 |
Qiagen GmbH |
Reverse transkription und amplifikation von rna bei simultaner degradierung von dna
|
US8299041B2
(en)
*
|
2005-04-08 |
2012-10-30 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to acetyl-CoA carboxylases
|
JP5329949B2
(ja)
|
2005-05-31 |
2013-10-30 |
エコーレ ポリテクニーク フェデラーレ デ ローザンヌ |
遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
|
WO2006138145A1
(en)
|
2005-06-14 |
2006-12-28 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
US8354384B2
(en)
*
|
2005-06-23 |
2013-01-15 |
Yale University |
Anti-aging micrornas
|
EP2239327B1
(de)
|
2005-08-11 |
2015-02-25 |
Synthetic Genomics, Inc. |
Verfahren zur In-Vitro-Rekombination
|
KR20080036646A
(ko)
|
2005-08-17 |
2008-04-28 |
메덱시스 에스.에이. |
Ck19 발현 측정을 위한 조성물 및 방법
|
EP2338991B1
(de)
|
2005-08-29 |
2017-01-18 |
Regulus Therapeutics Inc. |
Verfahren für MIR-122a-Modulation
|
EP1762627A1
(de)
|
2005-09-09 |
2007-03-14 |
Qiagen GmbH |
Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
|
WO2007035759A1
(en)
|
2005-09-19 |
2007-03-29 |
Johnson & Johnson Pharmaceutical Research & Development L.L.C. |
Modulation of glucocorticoid receptor expression
|
US20070087987A1
(en)
|
2005-09-19 |
2007-04-19 |
Monia Brett P |
Modulation of glucagon receptor expression
|
WO2007047512A2
(en)
|
2005-10-14 |
2007-04-26 |
Musc Foundation For Research Development |
Inhibition of pax2 by defb1 induction as a therapy for cancer
|
US8080534B2
(en)
*
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
EP1941059A4
(de)
|
2005-10-28 |
2010-11-03 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur hemmung der expression des huntingtin-gens
|
EP1945270B1
(de)
|
2005-11-09 |
2011-05-25 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und verfahren zur hemmung der expression von faktor v leiden mutationsgen
|
CA2630602A1
(en)
|
2005-11-21 |
2007-05-31 |
Isis Pharmaceuticals, Inc. |
Modulation of eif4e-bp2 expression
|
JP2009524411A
(ja)
*
|
2005-12-21 |
2009-07-02 |
イェール ユニバーシティー |
リボスイッチの調節に関連した方法および組成物
|
US8288354B2
(en)
|
2005-12-28 |
2012-10-16 |
The Scripps Research Institute |
Natural antisense and non-coding RNA transcripts as drug targets
|
JP2009522281A
(ja)
|
2005-12-28 |
2009-06-11 |
トランスレーショナル セラピューティクス,インク. |
翻訳機能障害に基づく治療法
|
EP1984499B1
(de)
|
2006-01-27 |
2015-05-27 |
Isis Pharmaceuticals, Inc. |
Oligomere verbindungen und zusammensetzungen zur verwendung bei der modulation von mikro-rnas
|
EP1984381B1
(de)
*
|
2006-01-27 |
2010-09-29 |
Isis Pharmaceuticals, Inc. |
6-modifizierte bicyclische nukleinsäureanaloga
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
WO2008029276A2
(en)
|
2006-02-02 |
2008-03-13 |
Allergan, Inc. |
Compositions and methods for the treatment of ophthalmic disease
|
CN101448849B
(zh)
|
2006-03-31 |
2013-08-21 |
阿尔尼拉姆医药品有限公司 |
抑制Eg5基因表达的组合物和方法
|
AU2007245599B2
(en)
*
|
2006-05-03 |
2012-05-10 |
Baltic Technology Development, Ltd. |
Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
|
DE102006020885A1
(de)
*
|
2006-05-05 |
2007-11-08 |
Qiagen Gmbh |
Einführung von Sequenzelementen in Nukleinsäuren
|
JP5825754B2
(ja)
|
2006-05-05 |
2015-12-02 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
Apobの発現を調節するための化合物および方法
|
ES2389737T3
(es)
*
|
2006-05-11 |
2012-10-31 |
Isis Pharmaceuticals, Inc. |
Análogos de ácidos nucleicos bicíclicos modificados en 5'
|
US7666854B2
(en)
*
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
BRPI0712034A2
(pt)
|
2006-05-19 |
2012-01-10 |
Alnylam Pharmaceuticals Inc |
modulação de rnai de aha e usos terapêuticos do mesmo
|
WO2007137220A2
(en)
|
2006-05-22 |
2007-11-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of ikk-b gene
|
US20090209625A1
(en)
*
|
2006-05-23 |
2009-08-20 |
Sanjay Bhanot |
Modulation of chrebp expression
|
US20090280188A1
(en)
*
|
2006-06-23 |
2009-11-12 |
Northwestern University |
Asymmetric functionalizated nanoparticles and methods of use
|
US8198253B2
(en)
|
2006-07-19 |
2012-06-12 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to HBXIP
|
WO2008033866A2
(en)
*
|
2006-09-11 |
2008-03-20 |
Yale University |
Methods and compositions for the use of lysine riboswitches
|
CA2663962A1
(en)
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
|
CA2664383C
(en)
|
2006-09-19 |
2017-08-22 |
Asuragen, Inc. |
Micrornas differentially expressed in pancreatic diseases and uses thereof
|
WO2008036825A2
(en)
*
|
2006-09-22 |
2008-03-27 |
Dharmacon, Inc. |
Duplex oligonucleotide complexes and methods for gene silencing by rna interference
|
MX2009003398A
(es)
|
2006-09-27 |
2009-08-12 |
Coley Pharm Gmbh |
Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
|
WO2008042156A1
(en)
*
|
2006-09-28 |
2008-04-10 |
Northwestern University |
Maximizing oligonucleotide loading on gold nanoparticle
|
US20080081210A1
(en)
*
|
2006-09-29 |
2008-04-03 |
General Electric Company |
Authenticatable articles and methods therefor
|
WO2008063758A2
(en)
|
2006-10-05 |
2008-05-29 |
Massachussetts Institute Of Technology |
Multifunctional encoded particles for high-throughput analysis
|
US8999317B2
(en)
|
2006-11-01 |
2015-04-07 |
University Of Rochester |
Methods and compositions related to the structure and function of APOBEC3G
|
KR20090089462A
(ko)
*
|
2006-12-11 |
2009-08-21 |
유니버시티 오브 유타 리써치 파운데이션 |
병적 혈관형성 및 혈관 투과성을 치료하기 위한 조성물 및 방법
|
EP2121987B1
(de)
|
2007-02-09 |
2012-06-13 |
Northwestern University |
Partikel zur erkennung intrazellulärer ziele
|
WO2008112218A2
(en)
|
2007-03-12 |
2008-09-18 |
Antigen Express, Inc. |
Li-rnai involved li suppression in cancer immunotherapy
|
CN101801185A
(zh)
|
2007-03-22 |
2010-08-11 |
耶鲁大学 |
与控制可变剪接的核糖开关有关的方法和组合物
|
AP2014007971A0
(en)
|
2007-03-29 |
2014-09-30 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expressionof a gene from the ebola
|
US11078262B2
(en)
|
2007-04-30 |
2021-08-03 |
Allergan, Inc. |
High viscosity macromolecular compositions for treating ocular conditions
|
AU2007353454C8
(en)
|
2007-05-11 |
2014-04-24 |
Rowan University |
Methods of treatment and prevention of neurodegenerative diseases and disorders
|
BRPI0810336A2
(pt)
|
2007-05-11 |
2019-03-19 |
The Trustees Of The University Of Pennsylvania |
"método para tratar e/ou prevenir úlceras de pele em um indivíduo"
|
EP2164994A4
(de)
*
|
2007-05-29 |
2010-07-21 |
Univ Yale Inc |
Verfahren und zusammensetzungen in verbindung mit riboswitches zu steuerung von alternativer spleissung und rna-verarbeitung
|
EP2164996A4
(de)
|
2007-05-29 |
2010-07-14 |
Univ Yale |
Riboswitches sowie verfahren und zusammensetzungen zur verwendung von und mit riboswitches
|
CA2688321A1
(en)
|
2007-05-30 |
2008-12-11 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
DK2826863T3
(en)
*
|
2007-05-30 |
2017-12-04 |
Univ Northwestern |
NUCLEIC ACID FUNCTIONALIZED NANOPARTICLES FOR THERAPEUTIC APPLICATIONS
|
US7807372B2
(en)
*
|
2007-06-04 |
2010-10-05 |
Northwestern University |
Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
|
WO2008154401A2
(en)
|
2007-06-08 |
2008-12-18 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
CA2691364C
(en)
|
2007-06-19 |
2020-06-16 |
Stratos Genomics, Inc. |
High throughput nucleic acid sequencing by expansion
|
ATE538127T1
(de)
*
|
2007-07-05 |
2012-01-15 |
Isis Pharmaceuticals Inc |
6-disubstituierte bicyclische nukleinsäureanaloga
|
CN101821277B
(zh)
|
2007-08-15 |
2014-05-07 |
Isis制药公司 |
四氢吡喃核酸类似物
|
US8557767B2
(en)
|
2007-08-28 |
2013-10-15 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
WO2009032693A2
(en)
*
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
WO2009039466A1
(en)
|
2007-09-20 |
2009-03-26 |
Vanderbilt University |
Free solution measurement of molecular interactions by backscattering interferometry
|
WO2009039442A1
(en)
*
|
2007-09-21 |
2009-03-26 |
California Institute Of Technology |
Nfia in glial fate determination, glioma therapy and astrocytoma treatment
|
CA2704560A1
(en)
*
|
2007-11-05 |
2009-05-14 |
Baltic Technology Development, Ltd. |
Use of oligonucleotides with modified bases in hybridization of nucleic acids
|
US8916531B2
(en)
*
|
2007-11-20 |
2014-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of CD40 expression
|
CA2708173C
(en)
|
2007-12-04 |
2016-02-02 |
Alnylam Pharmaceuticals, Inc. |
Targeting lipids
|
US7871985B2
(en)
|
2007-12-10 |
2011-01-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
US7845686B2
(en)
*
|
2007-12-17 |
2010-12-07 |
S & B Technical Products, Inc. |
Restrained pipe joining system for plastic pipe
|
CA3044134A1
(en)
|
2008-01-02 |
2009-07-09 |
Arbutus Biopharma Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
US9605035B2
(en)
|
2008-01-10 |
2017-03-28 |
Research Development Foundation |
Vaccines and diagnostics for the ehrlichioses
|
US8530640B2
(en)
*
|
2008-02-07 |
2013-09-10 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
CN102016036B
(zh)
|
2008-02-11 |
2015-04-08 |
阿克赛医药公司 |
经修饰的RNAi多核苷酸及其用途
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
AU2009222056A1
(en)
*
|
2008-03-01 |
2009-09-11 |
Abraxis Bioscience, Llc |
Treatment, diagnostic, and method for discovering antagonist using SPARC specific miRNAs
|
CA2716793A1
(en)
|
2008-03-05 |
2009-09-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 and vegf genes
|
EP2282744B1
(de)
|
2008-03-21 |
2018-01-17 |
Ionis Pharmaceuticals, Inc. |
Oligomere verbindungen mit trizyklischen nukleosiden und anwendungsverfahren dafür
|
EP2285819B1
(de)
*
|
2008-04-04 |
2013-10-16 |
Isis Pharmaceuticals, Inc. |
Oligomere verbindungen, die neutral gebundene, terminal bicyclische nukleoside enthalten
|
US8846639B2
(en)
|
2008-04-04 |
2014-09-30 |
Isis Pharmaceutical, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
WO2009126933A2
(en)
|
2008-04-11 |
2009-10-15 |
Alnylam Pharmaceuticals, Inc. |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
PL2281042T3
(pl)
|
2008-04-18 |
2016-01-29 |
Baxter Int |
Kompozycja na bazie mikrosfer do zapobiegania i/lub cofania nowego przypadku cukrzycy autoimmunologicznej
|
WO2009137660A2
(en)
*
|
2008-05-07 |
2009-11-12 |
Abraxis Bioscience, Llc |
Enhancement of drug therapy by mirna
|
US8258111B2
(en)
|
2008-05-08 |
2012-09-04 |
The Johns Hopkins University |
Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
EP2323667A4
(de)
*
|
2008-08-07 |
2012-07-25 |
Isis Pharmaceuticals Inc |
Modulierung der transthyretin-expression durch behandlung von zns-erkrankungen
|
JP5420668B2
(ja)
|
2008-08-25 |
2014-02-19 |
エクスカリアード・ファーマシューティカルズ,インコーポレイテッド |
結合組織成長因子を対象とするアンチセンスオリゴヌクレオチドおよびその使用
|
US8318693B2
(en)
|
2008-09-02 |
2012-11-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mutant EGFR gene
|
AU2009293658A1
(en)
|
2008-09-22 |
2010-03-25 |
James Cardia |
Reduced size self-delivering RNAi compounds
|
AU2009298802A1
(en)
|
2008-09-23 |
2010-04-08 |
Alnylam Pharmaceuticals, Inc. |
Chemical modifications of monomers and oligonucleotides with cycloaddition
|
US8604192B2
(en)
*
|
2008-09-24 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Cyclohexenyl nucleic acids analogs
|
EP2356129B1
(de)
*
|
2008-09-24 |
2013-04-03 |
Isis Pharmaceuticals, Inc. |
Substituierte alpha-l-bicyclische nukleoside
|
CA2739170A1
(en)
|
2008-09-25 |
2010-04-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
WO2010042877A1
(en)
|
2008-10-09 |
2010-04-15 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
CN103820450B
(zh)
|
2008-10-15 |
2018-08-21 |
Ionis制药公司 |
因子11表达的调节
|
US8168775B2
(en)
|
2008-10-20 |
2012-05-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
JP5763539B2
(ja)
|
2008-10-24 |
2015-08-12 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
5’及び2’ビス置換ヌクレオシド及びそれから製造されるオリゴマー化合物
|
US8987435B2
(en)
|
2008-10-24 |
2015-03-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
CA2743139C
(en)
|
2008-11-10 |
2019-04-02 |
Alnylam Pharmaceuticals, Inc. |
Novel lipids and compositions for the delivery of therapeutics
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
DK2365803T3
(en)
*
|
2008-11-24 |
2018-01-22 |
Univ Northwestern |
POLYVALENT RNA NANOPARTICLE COMPOSITIONS
|
JP5645840B2
(ja)
|
2008-12-02 |
2014-12-24 |
株式会社Wave Life Sciences Japan |
リン原子修飾核酸の合成方法
|
EP2370582B1
(de)
|
2008-12-04 |
2017-05-10 |
CuRNA, Inc. |
Behandlung von tumorsuppressorgen-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen das gen
|
WO2010065792A2
(en)
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
|
JP6099868B2
(ja)
|
2008-12-04 |
2017-03-22 |
クルナ・インコーポレーテッド |
サーチュイン1(sirt1)に対する天然アンチセンス転写物の抑制によるサーチュイン1関連疾患の治療
|
CA2746514C
(en)
|
2008-12-10 |
2018-11-27 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
WO2010081049A1
(en)
*
|
2009-01-08 |
2010-07-15 |
Northwestern University |
Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates
|
KR101546673B1
(ko)
*
|
2009-01-15 |
2015-08-25 |
삼성전자주식회사 |
전자 사진용 토너 및 그의 제조방법
|
WO2010088273A1
(en)
|
2009-01-27 |
2010-08-05 |
Qiagen Gaithersburg |
Thermophilic helicase dependent amplification technology with endpoint homogenous fluorescent detection
|
EP3243504A1
(de)
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Verbesserte lipidformulierung
|
EP2987864B1
(de)
|
2009-01-29 |
2018-04-25 |
Stratos Genomics Inc. |
Verfahren zur detektion eines analyten
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
WO2010090969A1
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
EP2393825A2
(de)
|
2009-02-06 |
2011-12-14 |
Isis Pharmaceuticals, Inc. |
Oligomere verbindungen und verfahren
|
CN102439149B
(zh)
|
2009-02-12 |
2018-01-02 |
库尔纳公司 |
通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
|
ES2762610T3
(es)
|
2009-02-12 |
2020-05-25 |
Curna Inc |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
EP3424939A1
(de)
|
2009-03-02 |
2019-01-09 |
Alnylam Pharmaceuticals Inc. |
Chemische nukleinsäuremodifikationen
|
JP6250263B2
(ja)
|
2009-03-04 |
2017-12-20 |
クルナ・インコーポレーテッド |
サーチュイン1(sirt1)に対する天然アンチセンス転写物の抑制によるsirt1関連疾患の治療
|
CN104922699B
(zh)
|
2009-03-12 |
2020-07-24 |
阿尔尼拉姆医药品有限公司 |
脂质配制的组合物以及用于抑制Eg5和VEGF基因表达的方法
|
US9464287B2
(en)
|
2009-03-16 |
2016-10-11 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
|
CN102549159B
(zh)
|
2009-03-17 |
2016-08-10 |
库尔纳公司 |
通过抑制针对δ样1同源物(DLK1)的天然反义转录物来治疗DLK1相关的疾病
|
US20110045080A1
(en)
*
|
2009-03-24 |
2011-02-24 |
William Marsh Rice University |
Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
|
AU2010237001B2
(en)
|
2009-04-15 |
2016-07-07 |
Northwestern University |
Delivery of oligonucleotide-functionalized nanoparticles
|
EP3248618A1
(de)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
|
US8318690B2
(en)
|
2009-05-01 |
2012-11-27 |
Curna, Inc. |
Treatment of hemoglobin (HBF/HBG) related diseases by inhibition of natural antisense transcript to HBF/HBG
|
EP3097908A1
(de)
|
2009-05-05 |
2016-11-30 |
Arbutus Biopharma Corporation |
Fettzusammensetzungen
|
US20100285112A1
(en)
|
2009-05-05 |
2010-11-11 |
Tatiana Novobrantseva |
Methods of delivering oligonucleotides to immune cells
|
CN102803492B
(zh)
|
2009-05-06 |
2016-06-29 |
库尔纳公司 |
通过抑制针对三重四脯氨酸(ttp)的天然反义转录物来治疗ttp相关疾病
|
CN103223177B
(zh)
|
2009-05-06 |
2016-08-10 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
WO2010132665A1
(en)
|
2009-05-15 |
2010-11-18 |
Yale University |
Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
|
EP2432881B1
(de)
|
2009-05-18 |
2017-11-15 |
CuRNA, Inc. |
Behandlung von krankheiten im zusammenhang mit dem reprogrammierungsfaktor durch hemmung des natürlichen antisense-transkripts zu einem reprogrammierungsfaktor
|
WO2010135564A2
(en)
*
|
2009-05-20 |
2010-11-25 |
Sena Research, Inc. |
Novel compounds and derivatization of dnas and rnas on the nucleobases of pyrimidines for function, structure, and therapeutics
|
CA2762987A1
(en)
|
2009-05-22 |
2010-11-25 |
Joseph Collard |
Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
|
JP5960049B2
(ja)
|
2009-05-28 |
2016-08-02 |
クルナ・インコーポレーテッド |
抗ウイルス遺伝子に対する天然アンチセンス転写物の抑制による抗ウイルス遺伝子関連疾患の治療
|
TR201811076T4
(tr)
|
2009-06-10 |
2018-08-27 |
Arbutus Biopharma Corp |
Geliştirilmiş lipit formulasyonu.
|
US20120171170A1
(en)
|
2009-06-16 |
2012-07-05 |
Opko Curna, Llc |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
JP6128846B2
(ja)
|
2009-06-16 |
2017-05-17 |
クルナ・インコーポレーテッド |
パラオキソナーゼ(pon1)に対する天然アンチセンス転写物の抑制によるpon1遺伝子関連疾患の治療
|
EP2446036B1
(de)
|
2009-06-24 |
2017-03-01 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit tumornekrose faktor-rezeptor 2 (tnfr2) mittels hemmung des natürlichen antisense-transkripts gegen tnfr2
|
CN102482672B
(zh)
|
2009-06-26 |
2016-11-09 |
库尔纳公司 |
通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
|
EP2451461A4
(de)
|
2009-07-06 |
2013-05-29 |
Ontorii Inc |
Neuartige nukleinsäure-prodrugs und verwendungsverfahren dafür
|
CN102762731B
(zh)
|
2009-08-05 |
2018-06-22 |
库尔纳公司 |
通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
|
EP2462153B1
(de)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclische cyclohexosenukleinsäureanaloga
|
EP2464336A4
(de)
|
2009-08-14 |
2013-11-20 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der expression eines gens aus dem ebolavirus
|
US20120157324A1
(en)
|
2009-08-17 |
2012-06-21 |
Yale University |
Methylation biomarkers and methods of use
|
WO2011031482A2
(en)
|
2009-08-25 |
2011-03-17 |
Curna, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
US9321823B2
(en)
|
2009-09-02 |
2016-04-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CA2778442A1
(en)
|
2009-10-22 |
2011-04-28 |
Genentech, Inc. |
Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
|
WO2011056687A2
(en)
|
2009-10-27 |
2011-05-12 |
Swift Biosciences, Inc. |
Polynucleotide primers and probes
|
DK2494075T3
(en)
|
2009-10-30 |
2018-07-23 |
Univ Northwestern |
TABLE-MANAGED NANOCONJUGATES
|
WO2011056215A1
(en)
|
2009-11-03 |
2011-05-12 |
Landers James P |
Versatile, visible method for detecting polymeric analytes
|
WO2011063403A1
(en)
|
2009-11-23 |
2011-05-26 |
Swift Biosciences, Inc. |
Devices to extend single stranded target molecules
|
AU2010324686B2
(en)
|
2009-11-30 |
2016-05-19 |
Genentech, Inc. |
Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 )
|
CA3044884A1
(en)
|
2009-12-07 |
2011-06-16 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
RU2639550C2
(ru)
|
2009-12-16 |
2017-12-21 |
Курна, Инк. |
Лечение заболеваний, связанных с сайт-1 мембраносвязанной пептидазой транскрипционных факторов (mbtps1), путем ингибирования природного антисмыслового транскрипта к mbtps1
|
EP2512449B1
(de)
|
2009-12-18 |
2019-08-07 |
The University of British Columbia |
Verfahren und zusammensetzungen zur abgabe von nukleinsäuren
|
KR101891352B1
(ko)
|
2009-12-23 |
2018-08-24 |
큐알엔에이, 인크. |
간세포 성장 인자(hgf)에 대한 천연 안티센스 전사체의 억제에 의한 hgf 관련 질환의 치료
|
CN102781480B
(zh)
|
2009-12-23 |
2018-07-27 |
库尔纳公司 |
通过抑制解偶联蛋白2(ucp2)的天然反义转录物而治疗ucp2相关疾病
|
WO2011090741A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
|
CA2785173A1
(en)
|
2009-12-29 |
2011-07-28 |
Curna, Inc. |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
US8946181B2
(en)
|
2010-01-04 |
2015-02-03 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
|
EP2521785B1
(de)
|
2010-01-06 |
2022-03-09 |
CuRNA, Inc. |
Inhibition des natürlichen antisense-transkripts des pankreasentwicklungsgens zur verwendung in der behandlung von pankreatischen entwicklungsgenbezogenen krankheiten
|
US9200277B2
(en)
|
2010-01-11 |
2015-12-01 |
Curna, Inc. |
Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
|
US8779118B2
(en)
|
2010-01-11 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2524042A2
(de)
|
2010-01-12 |
2012-11-21 |
Yale University |
Strukturierte rna-motive sowie verbindungen und verfahren zu ihrer verwendung
|
CA2786568A1
(en)
|
2010-01-25 |
2011-07-28 |
Curna, Inc. |
Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
|
US9198972B2
(en)
|
2010-01-28 |
2015-12-01 |
Alnylam Pharmaceuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
WO2011094580A2
(en)
|
2010-01-28 |
2011-08-04 |
Alnylam Pharmaceuticals, Inc. |
Chelated copper for use in the preparation of conjugated oligonucleotides
|
WO2011097407A1
(en)
|
2010-02-04 |
2011-08-11 |
Ico Therapeutics Inc. |
Dosing regimens for treating and preventing ocular disorders using c-raf antisense
|
JP5976548B2
(ja)
|
2010-02-22 |
2016-08-23 |
カッパーアールエヌエー,インコーポレイテッド |
Pycr1に対する天然アンチセンス転写物の阻害によるピロリン−5−カルボン酸レダクターゼ1(pycr1)関連疾患の治療
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
AU2011221226A1
(en)
|
2010-02-23 |
2012-08-16 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
ES2631458T3
(es)
|
2010-03-04 |
2017-08-31 |
Interna Technologies B.V. |
Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
WO2011113054A2
(en)
|
2010-03-12 |
2011-09-15 |
Aurasense Llc |
Crosslinked polynucleotide structure
|
ES2743600T3
(es)
|
2010-03-12 |
2020-02-20 |
Brigham & Womens Hospital Inc |
Métodos de tratamiento de los trastornos inflamatorios vasculares
|
WO2011115817A1
(en)
|
2010-03-16 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
Methods of preparing 2'-o-substituted purine nucleosides
|
WO2011115818A1
(en)
|
2010-03-17 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
KR101852210B1
(ko)
|
2010-03-24 |
2018-04-25 |
알엑스아이 파마슈티칼스 코포레이션 |
진피 및 섬유증성 적응증에서의 rna 간섭
|
RU2615143C2
(ru)
|
2010-03-24 |
2017-04-04 |
Адвирна |
Самодоставляющие PHKi соединения уменьшенного размера
|
EP2550001B1
(de)
|
2010-03-24 |
2019-05-22 |
Phio Pharmaceuticals Corp. |
Rna-interferenz bei augenerkrankungen
|
WO2011120046A2
(en)
|
2010-03-26 |
2011-09-29 |
Swift Biosciences, Inc. |
Methods and compositions for isolating polynucleotides
|
CA2792291A1
(en)
|
2010-03-29 |
2011-10-06 |
Kumamoto University |
Sirna therapy for transthyretin (ttr) related ocular amyloidosis
|
WO2011123621A2
(en)
|
2010-04-01 |
2011-10-06 |
Alnylam Pharmaceuticals Inc. |
2' and 5' modified monomers and oligonucleotides
|
CA2795281A1
(en)
|
2010-04-09 |
2011-10-13 |
Curna, Inc. |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
WO2011133695A2
(en)
|
2010-04-20 |
2011-10-27 |
Swift Biosciences, Inc. |
Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
|
US9725479B2
(en)
|
2010-04-22 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
5′-end derivatives
|
WO2011133876A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
US20130260460A1
(en)
|
2010-04-22 |
2013-10-03 |
Isis Pharmaceuticals Inc |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
WO2011139695A2
(en)
|
2010-04-28 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
|
JP6005628B2
(ja)
|
2010-04-28 |
2016-10-12 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物
|
EP2625186B1
(de)
|
2010-04-28 |
2016-07-27 |
Ionis Pharmaceuticals, Inc. |
5'-modifizierte nukleoside und daraus hergestellte oligomere verbindungen
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
KR20180026798A
(ko)
|
2010-04-29 |
2018-03-13 |
아이오니스 파마수티컬즈, 인코포레이티드 |
트랜스티레틴 발현의 조절
|
JP2013533732A
(ja)
|
2010-05-03 |
2013-08-29 |
ジェネンテック, インコーポレイテッド |
腫瘍の診断と治療のための組成物と方法
|
RU2693462C2
(ru)
|
2010-05-03 |
2019-07-03 |
Курна, Инк. |
Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
US8628914B2
(en)
|
2010-05-26 |
2014-01-14 |
Qiagen Gaithersburg, Inc. |
Quantitative helicase assay
|
RU2585229C2
(ru)
|
2010-05-26 |
2016-05-27 |
Курна, Инк. |
Лечение заболеваний, связанных с атональным гомологом 1 (атон1), путем ингибирования природного антисмыслового транскрипта гена атон1
|
WO2011150226A1
(en)
|
2010-05-26 |
2011-12-01 |
Landers James P |
Method for detecting nucleic acids based on aggregate formation
|
CA2801066C
(en)
|
2010-06-02 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
US8957200B2
(en)
|
2010-06-07 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2576839B1
(de)
|
2010-06-07 |
2017-05-10 |
Firefly Bioworks, Inc. |
Nukleinsäurenachweis und -quantifizierung durch posthybridisierungs-kennzeichnung und universelle kodierung
|
EP2580228B1
(de)
|
2010-06-08 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Substituierte 2 '-amino- und 2 '-thio-bicyclische nukleoside und daraus hergestellte oligomere verbindungen
|
WO2011156713A1
(en)
|
2010-06-11 |
2011-12-15 |
Vanderbilt University |
Multiplexed interferometric detection system and method
|
US9518259B2
(en)
|
2010-06-15 |
2016-12-13 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating interaction between proteins and target nucleic acids
|
US9168297B2
(en)
|
2010-06-23 |
2015-10-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Regulation of skin pigmentation by neuregulin-1 (NRG-1)
|
US8586301B2
(en)
|
2010-06-30 |
2013-11-19 |
Stratos Genomics, Inc. |
Multiplexed identification of nucleic acid sequences
|
CA2804599C
(en)
|
2010-07-06 |
2023-01-31 |
Interna Technologies Bv |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
JP5998131B2
(ja)
|
2010-07-14 |
2016-09-28 |
カッパーアールエヌエー,インコーポレイテッド |
Discslargehomolog(dlg)dlg1への天然アンチセンス転写物の阻害によるdlg関連疾患の治療
|
WO2012012443A2
(en)
|
2010-07-19 |
2012-01-26 |
Bennett C Frank |
Modulation of dystrophia myotonica-protein kinase (dmpk) expression
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
US20130202652A1
(en)
|
2010-07-30 |
2013-08-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
US20130143955A1
(en)
|
2010-08-09 |
2013-06-06 |
Yale University |
Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use
|
EP2620428B1
(de)
|
2010-09-24 |
2019-05-22 |
Wave Life Sciences Ltd. |
Asymmetrische hilfsgruppe
|
EP2625197B1
(de)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Smoothened-mutant und verfahren zu seiner anwendung
|
EP2625274B1
(de)
|
2010-10-06 |
2017-07-19 |
CuRNA, Inc. |
Behandlung sialidase-4-(neu4)-vermittelter erkrankungen durch hemmung des natürlichen antisense-transkripts gegen neu4
|
US20140031250A1
(en)
|
2010-10-07 |
2014-01-30 |
David Tsai Ting |
Biomarkers of Cancer
|
US8648053B2
(en)
|
2010-10-20 |
2014-02-11 |
Rosalind Franklin University Of Medicine And Science |
Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
|
KR20120042100A
(ko)
*
|
2010-10-22 |
2012-05-03 |
주식회사 씨젠 |
이중표지 고정화 프로브를 이용한 고상에서의 타겟 핵산서열 검출
|
US9222088B2
(en)
|
2010-10-22 |
2015-12-29 |
Curna, Inc. |
Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
|
DK2633052T3
(en)
|
2010-10-27 |
2018-07-16 |
Curna Inc |
TREATMENT OF INTERFERON-RELATED DEVELOPMENT REGULATOR 1 (IFRD1) -RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IFRD1
|
WO2012064824A1
(en)
|
2010-11-09 |
2012-05-18 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
DK2638163T3
(en)
|
2010-11-12 |
2017-07-24 |
Massachusetts Gen Hospital |
POLYCOMB-ASSOCIATED NON-CODING RNAs
|
AU2011329777B2
(en)
|
2010-11-17 |
2016-06-09 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
WO2012070965A1
(ru)
*
|
2010-11-22 |
2012-05-31 |
Farber Boris Slavinovich |
Модифицированные антикомплементарные олигонуклеотиды с противораковыми свойствами и способ их получения
|
RU2608493C2
(ru)
|
2010-11-23 |
2017-01-18 |
Курна, Инк. |
Лечение заболеваний, связанных с nanog, путем ингибирования природного антисмыслового транскрипта nanog
|
US9150926B2
(en)
|
2010-12-06 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Diagnosis and treatment of adrenocortical tumors using human microRNA-483
|
US9193973B2
(en)
|
2010-12-10 |
2015-11-24 |
Alynylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (EPO) production
|
US9127275B2
(en)
|
2010-12-10 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
WO2012099755A1
(en)
|
2011-01-11 |
2012-07-26 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
EP2474617A1
(de)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
MIR zur Behandlung von Neoangiogenese
|
EP2663323B1
(de)
|
2011-01-14 |
2017-08-16 |
The General Hospital Corporation |
Verfahren zur anzielung von mir-128 zur regelung des cholesterin-/fettstoffwechsels
|
CN103391777A
(zh)
|
2011-02-02 |
2013-11-13 |
普林斯顿大学理事会 |
作为病毒产生调节剂的去乙酰化酶调节剂
|
CN103635197A
(zh)
|
2011-02-02 |
2014-03-12 |
埃克斯利尔德生物制药公司 |
使用靶向结缔组织生长因子(ctgf)的反义化合物治疗疤痕疙瘩或肥大性疤痕的方法
|
EP3369828B1
(de)
|
2011-02-07 |
2020-07-15 |
The Governing Council Of The University Of Toronto |
Biosonden und verfahren zur verwendung davon
|
EP3467109A1
(de)
|
2011-02-08 |
2019-04-10 |
Ionis Pharmaceuticals, Inc. |
Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
|
US9562853B2
(en)
|
2011-02-22 |
2017-02-07 |
Vanderbilt University |
Nonaqueous backscattering interferometric methods
|
MX360349B
(es)
|
2011-03-29 |
2018-10-30 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
|
EP2694660B1
(de)
|
2011-04-03 |
2018-08-08 |
The General Hospital Corporation |
Effiziente in-vivo-proteinexpression mittels modifizierter rna (mod-rna)
|
US20140186844A1
(en)
|
2011-04-26 |
2014-07-03 |
Swift Biosciences, Inc. |
Polynucleotide primers and probes
|
WO2012151268A1
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system for high throughput optical and label free detection of analytes
|
US9353371B2
(en)
|
2011-05-02 |
2016-05-31 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
WO2012151289A2
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system to detect aggregate formation on a substrate
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
TWI678375B
(zh)
|
2011-06-09 |
2019-12-01 |
可娜公司 |
藉由抑制共濟蛋白(frataxin,fxn)之天然反股轉錄本治療fxn相關疾病
|
AU2012272860A1
(en)
|
2011-06-21 |
2013-12-19 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes
|
US9068184B2
(en)
|
2011-06-21 |
2015-06-30 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein C (PROC) genes
|
MX360782B
(es)
|
2011-06-21 |
2018-11-16 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni similares a angiopoyetina 3 (angptl3) y metodos para su uso.
|
EP3597750B1
(de)
|
2011-06-23 |
2022-05-04 |
Alnylam Pharmaceuticals, Inc. |
Serpina1-sirnas: materialzusammensetzungen und behandlungsverfahren
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
US9222093B2
(en)
|
2011-06-30 |
2015-12-29 |
The University Of Hong Kong |
Two-way, portable riboswitch mediated gene expression control device
|
US9605019B2
(en)
|
2011-07-19 |
2017-03-28 |
Wave Life Sciences Ltd. |
Methods for the synthesis of functionalized nucleic acids
|
WO2013019857A2
(en)
|
2011-08-01 |
2013-02-07 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
EP4269584A3
(de)
|
2011-08-11 |
2024-03-27 |
Ionis Pharmaceuticals, Inc. |
Selektive antisense-verbindungen und verwendungen davon
|
US9976138B2
(en)
|
2011-08-29 |
2018-05-22 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
WO2013033230A1
(en)
|
2011-08-29 |
2013-03-07 |
Isis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
WO2013040251A2
(en)
|
2011-09-13 |
2013-03-21 |
Asurgen, Inc. |
Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
|
JP2014526517A
(ja)
|
2011-09-14 |
2014-10-06 |
ノースウェスタン ユニバーシティ |
血液脳関門を通過することができるナノ抱合体
|
EP2756080B1
(de)
|
2011-09-14 |
2019-02-20 |
Translate Bio MA, Inc. |
Multimere oligonukleotidverbindungen
|
US9580713B2
(en)
|
2011-09-17 |
2017-02-28 |
Yale University |
Fluoride-responsive riboswitches, fluoride transporters, and methods of use
|
JP6250543B2
(ja)
|
2011-09-27 |
2017-12-20 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
ジ脂肪族置換peg化脂質
|
AU2012322788B2
(en)
|
2011-10-11 |
2018-01-04 |
The Brigham And Women's Hospital, Inc. |
Micrornas in neurodegenerative disorders
|
US20130157884A1
(en)
|
2011-10-26 |
2013-06-20 |
Asuragen, Inc. |
Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts
|
US9243291B1
(en)
|
2011-12-01 |
2016-01-26 |
Isis Pharmaceuticals, Inc. |
Methods of predicting toxicity
|
US10557136B2
(en)
|
2011-12-12 |
2020-02-11 |
Oncolmmunin Inc. |
In vivo delivery of oligonucleotides
|
EP3369818B1
(de)
|
2011-12-22 |
2021-06-09 |
InteRNA Technologies B.V. |
Mirna zur behandlung von kopf-hals-karzinom
|
EP2802674B1
(de)
|
2012-01-11 |
2020-12-16 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur modulation der ikbkap-aufspaltung
|
WO2013138536A1
(en)
|
2012-03-13 |
2013-09-19 |
Swift Biosciences, Inc. |
Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
|
HUE040179T2
(hu)
|
2012-03-15 |
2019-02-28 |
Curna Inc |
Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén
|
US9610362B2
(en)
|
2012-03-16 |
2017-04-04 |
Valerion Therapeutics, Llc |
Antisense conjugates for decreasing expression of DMPK
|
EP2831232A4
(de)
|
2012-03-30 |
2015-11-04 |
Univ Washington |
Verfahren zur modulation der tau-expression zur verringerung von anfällen und modifizierung eines neurodegenerativen syndroms
|
EP2850092B1
(de)
|
2012-04-09 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Tricyclische nukleinsäureanaloga
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
AU2013248981B2
(en)
|
2012-04-20 |
2018-11-29 |
Aptamir Therapeutics, Inc. |
Mirna modulators of thermogenesis
|
WO2013159108A2
(en)
|
2012-04-20 |
2013-10-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
US9273949B2
(en)
|
2012-05-11 |
2016-03-01 |
Vanderbilt University |
Backscattering interferometric methods
|
CN104583398A
(zh)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节基因表达的组合物和方法
|
DK2850186T3
(en)
|
2012-05-16 |
2019-04-08 |
Translate Bio Ma Inc |
COMPOSITIONS AND PROCEDURES FOR MODULATING SMN GENFAMILY EXPRESSION
|
US9574193B2
(en)
|
2012-05-17 |
2017-02-21 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating apolipoprotein (a) expression
|
WO2013173789A2
(en)
|
2012-05-17 |
2013-11-21 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
WO2013181665A1
(en)
|
2012-06-01 |
2013-12-05 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
WO2013181666A2
(en)
|
2012-06-01 |
2013-12-05 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
WO2013184209A1
(en)
|
2012-06-04 |
2013-12-12 |
Ludwig Institute For Cancer Research Ltd. |
Mif for use in methods of treating subjects with a neurodegenerative disorder
|
US20130330389A1
(en)
|
2012-06-08 |
2013-12-12 |
The Regents Of The University Of Michigan |
Ultrasound-triggerable agents for tissue engineering
|
BR112015000784A8
(pt)
|
2012-07-13 |
2018-04-03 |
Wave Life Sciences Japan |
Grupo auxiliar assimétrico
|
PL2872147T3
(pl)
|
2012-07-13 |
2023-09-25 |
Wave Life Sciences Ltd. |
Sposób wytwarzania chiralnych oligonukleotydów
|
RU2677639C2
(ru)
|
2012-07-13 |
2019-01-18 |
Шин Ниппон Биомедикал Лэбораториз, Лтд. |
Хиральный адъювант нуклеиновой кислоты
|
US20140038182A1
(en)
|
2012-07-17 |
2014-02-06 |
Dna Logix, Inc. |
Cooperative primers, probes, and applications thereof
|
US20150216892A1
(en)
|
2012-08-03 |
2015-08-06 |
Aptamir Therapeutics, Inc. |
Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
|
CN103571824B
(zh)
|
2012-08-09 |
2016-04-13 |
财团法人工业技术研究院 |
用于分离核酸的组合物及方法
|
KR102237882B1
(ko)
|
2012-08-15 |
2021-04-07 |
아이오니스 파마수티컬즈, 인코포레이티드 |
변형된 캡핑 프로토콜을 이용하는 올리고머 화합물 제조 방법
|
EP2892617B1
(de)
|
2012-09-06 |
2018-06-13 |
The University of Chicago |
Antisense-polynukleotide zur induktion von exon-skipping sowie verfahren zur behandlung von muskeldystrophien
|
WO2014045126A2
(en)
|
2012-09-18 |
2014-03-27 |
Uti Limited Partnership |
Treatment of pain by inhibition of usp5 de-ubiquitinase
|
US9212392B2
(en)
|
2012-09-25 |
2015-12-15 |
Exact Sciences Corporation |
Normalization of polymerase activity
|
US20140100124A1
(en)
|
2012-10-04 |
2014-04-10 |
Asuragen, Inc. |
Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions
|
EP2906699A4
(de)
|
2012-10-11 |
2016-06-08 |
Ionis Pharmaceuticals Inc |
Oligomere verbindungen mit bicyclischen nukleosiden und verwendungen davon
|
EP2906255B1
(de)
|
2012-10-12 |
2023-02-22 |
Ionis Pharmaceuticals, Inc. |
Antisense-verbindungen und verwendungen davon
|
US20150275208A1
(en)
|
2012-10-12 |
2015-10-01 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
CA2887702C
(en)
|
2012-10-26 |
2023-08-01 |
Geron Corporation |
C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
|
AU2013337277B2
(en)
|
2012-11-05 |
2018-03-08 |
Foundation Medicine, Inc. |
Novel NTRK1 fusion molecules and uses thereof
|
EP3800256A1
(de)
|
2012-11-06 |
2021-04-07 |
InteRNA Technologies B.V. |
Kombination zur therapeutischen verwendung bei krankheiten oder zuständen im zusammenhang mit melanomen oder bei krankheiten oder zuständen im zusammenhang mit dem aktivierten b-raf-signalweg
|
US9695475B2
(en)
|
2012-12-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Competitive modulation of microRNAs
|
EP2945652B1
(de)
|
2013-01-18 |
2021-07-07 |
Foundation Medicine, Inc. |
Verfahren zur behandlung cholangiokarzinom
|
WO2014121287A2
(en)
|
2013-02-04 |
2014-08-07 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
US20150366890A1
(en)
|
2013-02-25 |
2015-12-24 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
EP2961853B1
(de)
|
2013-02-28 |
2018-09-19 |
The Board of Regents of The University of Texas System |
Verfahren zur klassifizierung einer krebserkrankung als anfälligkeit für tmepai-gerichtete therapien und zur heilung solcher krebserkrankungen
|
BR112015022156A2
(pt)
|
2013-03-14 |
2017-11-14 |
Isis Pharmaceuticals Inc |
composições e métodos para modular a expressão de tau
|
RS56663B1
(sr)
|
2013-03-14 |
2018-03-30 |
Alnylam Pharmaceuticals Inc |
Irnk sastavi komponente komplementa c5 i metode za njihovu upotrebu
|
JP2016519083A
(ja)
|
2013-03-14 |
2016-06-30 |
アンデス バイオテクノロジーズ ソシエダード アノニマAndes Biotechnologies S.A. |
多発性骨髄腫を検出および処置するための方法
|
ES2708650T3
(es)
|
2013-03-14 |
2019-04-10 |
Andes Biotechnologies Global Inc |
Oligonucleótidos antisentido para el tratamiento de células madre tumorales
|
US20140287946A1
(en)
|
2013-03-14 |
2014-09-25 |
Ibis Biosciences, Inc. |
Nucleic acid control panels
|
WO2014144666A2
(en)
|
2013-03-15 |
2014-09-18 |
The University Of Chicago |
Methods and compositions related to t-cell activity
|
WO2014152054A1
(en)
|
2013-03-15 |
2014-09-25 |
Bio-Rad Laboratories, Inc. |
Digital assays for mutation detection
|
EP3708184A1
(de)
|
2013-03-27 |
2020-09-16 |
The General Hospital Corporation |
Verfahren und mittel zur behandlung von morbus alzheimer
|
JP2016522679A
(ja)
|
2013-04-04 |
2016-08-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
CRISPR/Cas系を用いたゲノム編集の治療的使用
|
US20140309276A1
(en)
*
|
2013-04-12 |
2014-10-16 |
Artur Martynov |
Pharmaceutical Composition Comprising a Mixture of Carboxylated Oligonucleotides
|
US9677075B2
(en)
|
2013-04-23 |
2017-06-13 |
Northwestern University |
Metal-ligand coordination polymer nanoparticles and methods for making
|
CN105378085B
(zh)
|
2013-05-01 |
2019-02-15 |
Ionis制药公司 |
用于调节hbv和ttr表达的组合物和方法
|
SG10201804472YA
(en)
|
2013-05-22 |
2018-07-30 |
Alnylam Pharmaceuticals Inc |
SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
AU2014268529C1
(en)
|
2013-05-22 |
2020-10-01 |
Alnylam Pharmaceuticals, Inc. |
TMPRSS6 iRNA compositions and methods of use thereof
|
EP3004396B1
(de)
|
2013-06-06 |
2019-10-16 |
The General Hospital Corporation |
Zusammensetzungen zur krebsbehandlung
|
DK3007704T3
(da)
|
2013-06-13 |
2021-03-29 |
Antisense Therapeutics Ltd |
Kombinationsterapi til akromegali
|
EP3011028B1
(de)
|
2013-06-21 |
2019-06-12 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur modulation von zielnukleinsäuren
|
EP3022176B8
(de)
|
2013-07-15 |
2019-12-25 |
The Regents of the University of California |
Eingeschränkte azacyclische analoga von fty720
|
TWI772856B
(zh)
|
2013-07-19 |
2022-08-01 |
美商百健Ma公司 |
用於調節τ蛋白表現之組合物
|
US10435430B2
(en)
|
2013-07-31 |
2019-10-08 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
PT3041854T
(pt)
|
2013-08-08 |
2020-03-05 |
Scripps Research Inst |
Um método para a identificação enzimática específica ao local de ácidos nucleicos in vitro pela incorporação de nucleótidos não-naturais
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
WO2015042447A1
(en)
|
2013-09-20 |
2015-03-26 |
Isis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
TW202003849A
(zh)
|
2013-10-02 |
2020-01-16 |
美商艾爾妮蘭製藥公司 |
抑制lect2基因表現之組合物及方法
|
NZ757749A
(en)
|
2013-10-04 |
2022-07-01 |
Icahn School Med Mount Sinai |
Compositions and methods for inhibiting expression of the alas1 gene
|
US10584387B2
(en)
|
2013-10-09 |
2020-03-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Detection of hepatitis delta virus (HDV) for the diagnosis and treatment of Sjögren's syndrome and lymphoma
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
CA2928779A1
(en)
|
2013-10-21 |
2015-04-30 |
The General Hospital Corporation |
Methods relating to circulating tumor cell clusters and the treatment of cancer
|
US10301622B2
(en)
|
2013-11-04 |
2019-05-28 |
Northwestern University |
Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (SNA)
|
WO2015070173A1
(en)
|
2013-11-08 |
2015-05-14 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for detecting oligonucleotides
|
EP3065706A4
(de)
|
2013-11-08 |
2017-11-29 |
Baylor Research Institute |
Nukleare lokalisierung von glp-1 zur stimulation der herzmuskelregenerierung und reversion von herzversagen
|
JP6772062B2
(ja)
|
2013-12-02 |
2020-10-21 |
フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. |
癌の免疫療法
|
US20170268000A1
(en)
|
2013-12-02 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
JP6527516B2
(ja)
|
2013-12-03 |
2019-06-05 |
ノースウェスタン ユニバーシティ |
リポソーム粒子、前述のものを作製する方法及びその使用
|
CA2844640A1
(en)
|
2013-12-06 |
2015-06-06 |
The University Of British Columbia |
Method for treatment of castration-resistant prostate cancer
|
US10385388B2
(en)
|
2013-12-06 |
2019-08-20 |
Swift Biosciences, Inc. |
Cleavable competitor polynucleotides
|
CA3107872A1
(en)
|
2013-12-12 |
2015-06-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component irna compositions and methods of use thereof
|
US10900083B2
(en)
|
2013-12-20 |
2021-01-26 |
The General Hospital Corporation |
Methods and assays relating to circulating tumor cells
|
US10144933B2
(en)
|
2014-01-15 |
2018-12-04 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
|
EP3095459A4
(de)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chirales nukleinsäureadjuvans mit antitumorwirkung und antitumormittel
|
WO2015108046A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
|
CN113278617A
(zh)
|
2014-01-16 |
2021-08-20 |
波涛生命科学有限公司 |
手性设计
|
US20170044232A1
(en)
|
2014-02-04 |
2017-02-16 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EP3960860A3
(de)
|
2014-02-11 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2015123551A1
(en)
|
2014-02-13 |
2015-08-20 |
Du Luqin |
Microrna composition for the treatment of neuroblastoma
|
EP3119789B1
(de)
|
2014-03-17 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Bicyclische carbocyclische nukleoside und daraus hergestellte oligomere verbindungen
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
SG10201808063PA
(en)
|
2014-03-19 |
2018-10-30 |
Ionis Pharmaceuticals Inc |
Compositions for modulating ataxin 2 expression
|
MX2016012922A
(es)
|
2014-04-01 |
2017-01-26 |
Ionis Pharmaceuticals Inc |
Composiciones para modular la expresion de sod-1.
|
WO2015157555A2
(en)
|
2014-04-09 |
2015-10-15 |
The Scripps Research Institute |
Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
|
US10221416B2
(en)
|
2014-04-24 |
2019-03-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
EP3137476B1
(de)
|
2014-04-28 |
2019-10-09 |
Ionis Pharmaceuticals, Inc. |
Verbindungsmodifizierte oligomerverbindungen
|
WO2015168108A2
(en)
|
2014-04-28 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treating cancer using nucleic targeting mdm2 or mycn
|
MX2016014102A
(es)
|
2014-05-01 |
2017-05-03 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3.
|
PE20190626A1
(es)
|
2014-05-01 |
2019-04-26 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion del factor b del complemento
|
CN106459969B
(zh)
|
2014-05-01 |
2019-11-15 |
Ionis制药公司 |
用于调节生长激素受体表达的组合物和方法
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
WO2015179693A1
(en)
|
2014-05-22 |
2015-11-26 |
Isis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
CN112852809A
(zh)
|
2014-05-22 |
2021-05-28 |
阿尔尼拉姆医药品有限公司 |
血管紧张素原(AGT)iRNA组合物及其使用方法
|
KR20170031668A
(ko)
|
2014-06-02 |
2017-03-21 |
칠드런'즈 메디컬 센터 코포레이션 |
면역 조절을 위한 방법 및 조성물
|
KR102524543B1
(ko)
|
2014-06-10 |
2023-04-20 |
에라스무스 유니버시티 메디컬 센터 로테르담 |
폼페병의 치료에 유용한 안티센스 올리고뉴클레오티드
|
US10301624B2
(en)
|
2014-06-25 |
2019-05-28 |
The General Hospital Corporation |
Targeting human satellite II (HSATII)
|
US9951327B1
(en)
|
2014-07-17 |
2018-04-24 |
Integrated Dna Technologies, Inc. |
Efficient and rapid method for assembling and cloning double-stranded DNA fragments
|
IL250302B
(en)
|
2014-07-31 |
2022-07-01 |
Uab Research Foundation |
Apoe mimetic peptides with high potency to clear plasma cholesterol
|
US20170232109A1
(en)
|
2014-08-19 |
2017-08-17 |
Northwestern University |
Protein/oligonucleotide core-shell nanoparticle therapeutics
|
KR20170042758A
(ko)
|
2014-08-20 |
2017-04-19 |
노오쓰웨스턴 유니버시티 |
안티센스 유전자 조절을 위한 생체에 적합한 무한 배위 중합체 나노입자-핵산 컨쥬게이트
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
WO2016033326A2
(en)
|
2014-08-29 |
2016-03-03 |
Alnylam Pharmaceuticals, Inc. |
Methods of treating transthyretin (ttr) mediated amyloidosis
|
US10385343B2
(en)
|
2014-08-29 |
2019-08-20 |
Children's Medical Center Corporation |
Methods and compositions for the treatment of cancer
|
KR20230037676A
(ko)
|
2014-09-05 |
2023-03-16 |
피오 파마슈티칼스 코프. |
Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
|
EP3191591A1
(de)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
|
JP6841753B2
(ja)
|
2014-09-15 |
2021-03-10 |
ザ チルドレンズ メディカル センター コーポレーション |
ヒストンh3−リジントリメチル化を除去することによって体細胞核移入(scnt)効率を増加させるための方法および組成物
|
EP3663403A1
(de)
|
2014-09-26 |
2020-06-10 |
University of Massachusetts |
Rna-modulierende stoffe
|
WO2016057693A1
(en)
|
2014-10-10 |
2016-04-14 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
EP3904519A1
(de)
|
2014-10-30 |
2021-11-03 |
Genzyme Corporation |
Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
WO2016077540A1
(en)
|
2014-11-12 |
2016-05-19 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of comp
|
CA2968114A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
WO2016081871A1
(en)
|
2014-11-20 |
2016-05-26 |
Stratos Genomics, Inc. |
Nulceoside phosphoroamidate esters and derivatives thereof, use and synthesis thereof
|
KR20170078843A
(ko)
|
2014-11-21 |
2017-07-07 |
노오쓰웨스턴 유니버시티 |
구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수
|
WO2016094342A1
(en)
|
2014-12-08 |
2016-06-16 |
The Board Of Regents Of The University Of Texas System |
Lipocationic polymers and uses thereof
|
EP3230445B1
(de)
|
2014-12-12 |
2024-01-24 |
Tod M. Woolf |
Zusammensetzungen und verfahren zur editierung von nukleinsäuren in zellen mit oligonukleotiden
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
JP2018506715A
(ja)
|
2015-01-23 |
2018-03-08 |
ヴァンダービルト ユニバーシティー |
堅固なインターフェロメーター及びその使用方法
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
EP3256587A2
(de)
|
2015-02-13 |
2017-12-20 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing-3 (pnpla3)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP3259346A4
(de)
|
2015-02-20 |
2018-07-11 |
Baylor College of Medicine |
P63-inaktivierung zur behandlung von herzinsuffizienz
|
EP3262173A2
(de)
|
2015-02-23 |
2018-01-03 |
Crispr Therapeutics AG |
Materialien und verfahren zur behandlung von humangenetischen erkrankungen einschliesslich hämoglobinopathien
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
CN107847524A
(zh)
|
2015-03-27 |
2018-03-27 |
哈佛学院校长同事会 |
经过修饰的t细胞及其制备和使用方法
|
EP3283502A4
(de)
|
2015-04-07 |
2019-04-03 |
The General Hospital Corporation |
Verfahren zur reaktivierung von genen auf dem inaktiven x-chromosom
|
ES2846902T3
(es)
|
2015-04-08 |
2021-07-30 |
Univ Chicago |
Composiciones y procedimientos para corregir la distrofia muscular de cinturas tipo 2C mediante omisión de exones
|
MX2017012610A
(es)
|
2015-04-08 |
2018-03-16 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen lect2.
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
EP3307316A1
(de)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
EP3314250A4
(de)
|
2015-06-26 |
2018-12-05 |
Beth Israel Deaconess Medical Center, Inc. |
Auf tetraspanin 33 (tspann33) in myeloidabgeleiteten suppressorzellen abzielende krebstherapie
|
WO2017004261A1
(en)
|
2015-06-29 |
2017-01-05 |
Ionis Pharmaceuticals, Inc. |
Modified crispr rna and modified single crispr rna and uses thereof
|
CA2991045A1
(en)
|
2015-06-29 |
2017-01-05 |
Caris Science, Inc. |
Therapeutic oligonucleotides binding c1q
|
WO2017007825A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
CA2991598A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
CN109477106B
(zh)
|
2015-07-10 |
2022-10-04 |
Ionis制药公司 |
二酰基甘油酰基转移酶2(dgat2)的调节剂
|
MA43072A
(fr)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
WO2017019918A1
(en)
|
2015-07-28 |
2017-02-02 |
Caris Science, Inc. |
Targeted oligonucleotides
|
WO2017021961A1
(en)
|
2015-08-04 |
2017-02-09 |
Yeda Research And Development Co. Ltd. |
Methods of screening for riboswitches and attenuators
|
EP3344769B1
(de)
|
2015-09-02 |
2024-04-17 |
Alnylam Pharmaceuticals, Inc. |
Programmed cell death 1 ligand 1 (pd-l1) irna-kompositionen und methoden zu deren verwendung
|
CN108271360B
(zh)
|
2015-09-14 |
2023-01-24 |
得克萨斯州大学系统董事会 |
亲脂阳离子树枝状聚合物及其用途
|
JP6853539B2
(ja)
|
2015-09-24 |
2021-03-31 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
合成スフィンゴ脂質様分子、薬物、これらの合成方法、および処置方法
|
JP6877414B2
(ja)
|
2015-09-24 |
2021-05-26 |
アイオニス・ファーマシューティカルズ・インコーポレイテッドIonis Pharmaceuticals,Inc. |
Kras発現のモジュレーター
|
WO2017064546A1
(en)
|
2015-09-24 |
2017-04-20 |
Crispr Therapeutics Ag |
Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
|
WO2017053781A1
(en)
|
2015-09-25 |
2017-03-30 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating ataxin 3 expression
|
US10709812B2
(en)
|
2015-09-29 |
2020-07-14 |
The Regents Of The University Of Michigan |
Biodegradable hydrogel for tissue expansion
|
MX2018004637A
(es)
|
2015-10-14 |
2019-05-06 |
Bio Path Holdings Inc |
Ácidos nucleicos p-etoxi para formulacion liposomal.
|
US11021707B2
(en)
|
2015-10-19 |
2021-06-01 |
Phio Pharmaceuticals Corp. |
Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
|
EP3368063B1
(de)
|
2015-10-28 |
2023-09-06 |
Vertex Pharmaceuticals Inc. |
Materialien und verfahren zur behandlung von duchenne-muskeldystrophie
|
CA3002196A1
(en)
|
2015-10-30 |
2017-05-04 |
Exact Sciences Development Company, Llc |
Multiplex amplification detection assay and isolation and detection of dna from plasma
|
CA3007424A1
(en)
|
2015-11-05 |
2017-05-11 |
Children's Hospital Los Angeles |
"mobilizing leukemia cells"
|
CA2999649A1
(en)
|
2015-11-06 |
2017-05-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of glycogen storage disease type 1a
|
US10557137B2
(en)
|
2015-11-06 |
2020-02-11 |
Ionis Pharmaceuticals, Inc. |
Modulating apolipoprotein (a) expression
|
WO2017079745A1
(en)
|
2015-11-06 |
2017-05-11 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds for use in therapy
|
WO2017087281A1
(en)
|
2015-11-16 |
2017-05-26 |
Stratos Genomics, Inc. |
Dp04 polymerase variants
|
AU2016355178B9
(en)
|
2015-11-19 |
2019-05-30 |
Massachusetts Institute Of Technology |
Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
|
JP6932698B2
(ja)
|
2015-12-01 |
2021-09-08 |
クリスパー・セラピューティクス・アクチェンゲゼルシャフトCRISPR Therapeutics AG |
アルファ1アンチトリプシン欠乏症の治療のための材料および方法
|
WO2017096395A1
(en)
|
2015-12-04 |
2017-06-08 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
AU2015416656B2
(en)
|
2015-12-07 |
2023-02-23 |
Erasmus University Medical Center Rotterdam |
Enzymatic replacement therapy and antisense therapy for Pompe disease
|
WO2017106767A1
(en)
|
2015-12-18 |
2017-06-22 |
The Scripps Research Institute |
Production of unnatural nucleotides using a crispr/cas9 system
|
JP6947729B2
(ja)
|
2015-12-23 |
2021-10-13 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
筋萎縮性側索硬化症及び/または前頭側頭葉変性症の治療のための材料及び方法
|
US10907160B2
(en)
|
2016-01-05 |
2021-02-02 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing LRRK2 expression
|
US10627396B2
(en)
|
2016-01-29 |
2020-04-21 |
Vanderbilt University |
Free-solution response function interferometry
|
WO2017134529A1
(en)
|
2016-02-02 |
2017-08-10 |
Crispr Therapeutics Ag |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
CA3019952A1
(en)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
EP3416689B1
(de)
|
2016-02-18 |
2023-01-18 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von schwerer kombinierter immundefizienz (scid) oder omenn syndrome
|
JP7033072B2
(ja)
|
2016-02-25 |
2022-03-09 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
Smoc2を標的化する線維症のための治療方法
|
EP3423581A4
(de)
|
2016-03-04 |
2020-03-04 |
Rhode Island Hospital |
Targeting von mikrorna zur krebsbehandlung
|
EP3426349A4
(de)
|
2016-03-09 |
2020-01-01 |
Ionis Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur hemmung der pmp22-expression
|
US10577607B2
(en)
|
2016-03-16 |
2020-03-03 |
Ionis Pharmaceuticals, Inc. |
Modulation of DYRK1B expression
|
CA3013799A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating keap1
|
EP3429632B1
(de)
|
2016-03-16 |
2023-01-04 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von erblicher haemochromatose
|
KR20190008843A
(ko)
|
2016-03-18 |
2019-01-25 |
카리스 싸이언스, 인코포레이티드 |
올리고뉴클레오티드 프로브 및 이의 용도
|
EP3436049B1
(de)
|
2016-03-31 |
2022-01-12 |
Baylor Research Institute |
Angiopoietin-ähnliches protein 8 (angptl8)
|
EP3443094B1
(de)
|
2016-04-13 |
2022-10-19 |
Ionis Pharmaceuticals, Inc. |
Verfahren zur reduzierung der c9orf72-expression
|
MX2018012729A
(es)
|
2016-04-18 |
2019-07-04 |
Crispr Therapeutics Ag |
Materiales y metodos para el tratamiento de hemoglobinopatias.
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
WO2017191503A1
(en)
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
CN116064796A
(zh)
|
2016-05-05 |
2023-05-05 |
精密科学公司 |
通过分析甲基化dna来检测肺肿瘤
|
JP7080826B2
(ja)
|
2016-05-16 |
2022-06-06 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質
|
US11293017B2
(en)
|
2016-05-25 |
2022-04-05 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
EP3469083A1
(de)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh)
|
EP3472350B1
(de)
|
2016-06-15 |
2022-08-17 |
Streck, Inc. |
Test und verfahren zu bestimmung mikrobieller resistenz
|
US11236339B2
(en)
|
2016-06-17 |
2022-02-01 |
Ionis Pharmaceuticals, Inc. |
Modulation of GYS1 expression
|
WO2017223528A1
(en)
|
2016-06-24 |
2017-12-28 |
The Scripps Research Institute |
Novel nucleoside triphosphate transporter and uses thereof
|
EP3478829A1
(de)
|
2016-06-29 |
2019-05-08 |
Crispr Therapeutics AG |
Materialien und verfahren zur behandlung von myotoner dystrophie typ 1 (dm1) und anderen erkrankungen
|
EP3478313B1
(de)
|
2016-06-29 |
2022-05-04 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von amyotropher lateralsklerose (als) und anderen verwandten erkrankungen
|
AU2017290614C1
(en)
|
2016-06-29 |
2024-01-18 |
Crispr Therapeutics Ag |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
CN109843914B
(zh)
|
2016-07-06 |
2024-03-15 |
沃泰克斯药物股份有限公司 |
用于治疗疼痛相关病症的材料和方法
|
US11801313B2
(en)
|
2016-07-06 |
2023-10-31 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
AU2017296195A1
(en)
|
2016-07-11 |
2019-01-24 |
Translate Bio Ma, Inc. |
Nucleic acid conjugates and uses thereof
|
PT3484524T
(pt)
|
2016-07-15 |
2023-02-15 |
Ionis Pharmaceuticals Inc |
Composições e métodos para a modulação de smn2
|
WO2018020323A2
(en)
|
2016-07-25 |
2018-02-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of fatty acid disorders
|
NL2017295B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Antisense oligomeric compound for Pompe disease
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
US11364304B2
(en)
|
2016-08-25 |
2022-06-21 |
Northwestern University |
Crosslinked micellar spherical nucleic acids
|
SG10201607303YA
(en)
|
2016-09-01 |
2018-04-27 |
Agency Science Tech & Res |
Antisense oligonucleotides to induce exon skipping
|
SG10202008771WA
(en)
|
2016-09-16 |
2020-10-29 |
Bio Path Holdings Inc |
Combination therapy with liposomal antisense oligonucleotides
|
WO2018055577A1
(en)
|
2016-09-23 |
2018-03-29 |
Synthena Ag |
Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
|
JOP20190065A1
(ar)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن tau
|
WO2018067900A1
(en)
|
2016-10-06 |
2018-04-12 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
SG10201609048RA
(en)
|
2016-10-28 |
2018-05-30 |
Agency Science Tech & Res |
Antisense oligonucleotides
|
CA3037046A1
(en)
|
2016-10-31 |
2018-05-03 |
University Of Massachusetts |
Targeting microrna-101-3p in cancer therapy
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
US11033570B2
(en)
|
2016-12-02 |
2021-06-15 |
Cold Spring Harbor Laboratory |
Modulation of Lnc05 expression
|
EP3555296A4
(de)
|
2016-12-13 |
2020-07-29 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Verfahren zur exogenen wirkstoffaktivierung von chemisch induzierten signalisierungskomplexen, die in vitro und in vivo in manipulierten zellen exprimiert werden
|
WO2018112320A1
(en)
|
2016-12-16 |
2018-06-21 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
JP7458785B2
(ja)
|
2017-01-23 |
2024-04-01 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒドロキシステロイド17-βデヒドロゲナーゼ13(HSD17B13)バリアント及びその使用
|
EP4253565A2
(de)
|
2017-01-24 |
2023-10-04 |
Vastogen, Inc. |
Verfahren zur konstruktion von kopien von nukleinsäuremolekülen
|
JP7289264B2
(ja)
|
2017-01-27 |
2023-06-09 |
エグザクト サイエンシーズ コーポレーション |
メチル化dnaの分析による結腸腫瘍の検出
|
WO2018154462A2
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
|
WO2018154459A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
|
WO2018154418A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
EP3585898A1
(de)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von spinozerebellärer ataxie typ 1 (sca1) und anderen mit dem gen des proteins von spinozerebellärer ataxie typ 1 (atxn1) assoziierten erkrankungen oder störungen
|
CA3054031A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
US11180756B2
(en)
|
2017-03-09 |
2021-11-23 |
Ionis Pharmaceuticals |
Morpholino modified oligomeric compounds
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
US20180284123A1
(en)
|
2017-03-30 |
2018-10-04 |
California Institute Of Technology |
Barcoded rapid assay platform useful for efficient analysis of candidate molecules and methods of making and using the platform
|
CA3058966A1
(en)
|
2017-04-14 |
2018-10-18 |
Tollnine, Inc. |
Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
|
BR112019021852A2
(pt)
|
2017-04-18 |
2020-06-02 |
Alnylam Pharmaceuticals, Inc. |
Agente de rnai e uma vacina contra hbv, uso ou método e kit para tratamento
|
EP4036101A1
(de)
|
2017-04-20 |
2022-08-03 |
Synthena AG |
Modifizierte oligomere verbindungen mit tricyclischen dna-nukleosiden und verwendungen davon
|
WO2018193428A1
(en)
|
2017-04-20 |
2018-10-25 |
Synthena Ag |
Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
|
US20200384115A1
(en)
|
2017-04-21 |
2020-12-10 |
The Broad Institute , Inc. |
Targeted delivery to beta cells
|
WO2018204707A1
(en)
|
2017-05-04 |
2018-11-08 |
Stratos Genomics Inc. |
Dp04 polymerase variants
|
WO2018209270A1
(en)
|
2017-05-11 |
2018-11-15 |
Northwestern University |
Adoptive cell therapy using spherical nucleic acids (snas)
|
AU2018367896B2
(en)
|
2017-05-12 |
2023-06-01 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
EA202090752A1
(ru)
*
|
2017-06-16 |
2020-06-15 |
Борис Славинович ФАРБЕР |
Комбинаторные производные олигонуклеотидов рнк
|
US11597744B2
(en)
|
2017-06-30 |
2023-03-07 |
Sirius Therapeutics, Inc. |
Chiral phosphoramidite auxiliaries and methods of their use
|
AR112756A1
(es)
|
2017-07-11 |
2019-12-11 |
Synthorx Inc |
Incorporación de nucleótidos no naturales, y su método
|
CA3069868A1
(en)
|
2017-07-13 |
2019-01-17 |
Alnylam Pharmaceuticals Inc. |
Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
|
EP3652186A4
(de)
|
2017-07-13 |
2021-03-31 |
Northwestern University |
Allgemeines und direktes verfahren zur herstellung von oligonukleotidfunktionalisierten metallorganischen gerüstnanopartikeln
|
EP3661955A4
(de)
|
2017-08-03 |
2021-05-26 |
Synthorx, Inc. |
Cytokin-konjugate zur behandlung von autoimmunerkrankungen
|
EP3668984A4
(de)
|
2017-08-18 |
2021-09-08 |
Ionis Pharmaceuticals, Inc. |
Modulation des notch-signalweges zur behandlung von atemwegserkrankungen
|
WO2019051173A1
(en)
|
2017-09-08 |
2019-03-14 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF SMAD7 EXPRESSION
|
KR20200089656A
(ko)
|
2017-09-19 |
2020-07-27 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법
|
MA50833A
(fr)
|
2017-10-17 |
2020-08-26 |
Bayer Healthcare Llc |
Compositions et méthodes pour l'édition génique pour l'hémophilie a
|
MA50849A
(fr)
|
2017-10-26 |
2020-09-02 |
Vertex Pharma |
Substances et procédés pour le traitement d'hémoglobinopathies
|
WO2019089922A1
(en)
|
2017-11-01 |
2019-05-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
CN111566212A
(zh)
|
2017-11-03 |
2020-08-21 |
因特尔纳技术有限公司 |
miRNA分子,等同物,安塔够妙或其来源用于治疗和/或诊断与神经元缺陷相关的病症和/或疾病或用于神经元生成和/或再生
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
US20210363521A1
(en)
|
2017-11-09 |
2021-11-25 |
Vertex Pharmaceuticals Incorporated |
CRISPR/CAS Systems For Treatment of DMD
|
EP3710587A1
(de)
|
2017-11-16 |
2020-09-23 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein-c3 kisspeptin 1 (kiss1)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
US20190153440A1
(en)
|
2017-11-21 |
2019-05-23 |
Casebia Therapeutics Llp |
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
|
WO2019113149A1
(en)
|
2017-12-05 |
2019-06-13 |
Crispr Therapeutics Ag |
Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
|
CA3084812A1
(en)
|
2017-12-11 |
2019-06-20 |
Stratos Genomics, Inc. |
Dpo4 polymerase variants with improved accuracy
|
US10648025B2
(en)
|
2017-12-13 |
2020-05-12 |
Exact Sciences Development Company, Llc |
Multiplex amplification detection assay II
|
EP3724206B1
(de)
|
2017-12-14 |
2023-06-28 |
Ionis Pharmaceuticals, Inc. |
Konjugierte antisense-verbindungen und deren verwendung
|
CA3084825A1
(en)
|
2017-12-14 |
2019-06-20 |
Crispr Therapeutics Ag |
Novel rna-programmable endonuclease systems and their use in genome editing and other applications
|
CA3086343A1
(en)
|
2017-12-18 |
2019-06-27 |
Alnylam Pharmaceuticals, Inc. |
High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
|
EP3728281A1
(de)
|
2017-12-21 |
2020-10-28 |
Alnylam Pharmaceuticals Inc. |
Chiral angereicherte doppelsträngige rna-wirkstoffe
|
CA3084633A1
(en)
|
2017-12-21 |
2019-06-27 |
Crispr Therapeutics Ag |
Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
AU2018393050A1
(en)
|
2017-12-21 |
2020-06-18 |
Bayer Healthcare Llc |
Materials and methods for treatment of Usher Syndrome Type 2A
|
MA51637A
(fr)
|
2018-01-12 |
2020-11-18 |
Bayer Healthcare Llc |
Compositions et méthodes pour l'édition génique par ciblage de la transferrine
|
AU2019208006A1
(en)
|
2018-01-12 |
2020-07-23 |
Bristol-Myers Squibb Company |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
TW201934129A
(zh)
|
2018-01-15 |
2019-09-01 |
美商Ionis製藥公司 |
Dnm2表現之調節劑
|
US20200369639A1
(en)
|
2018-01-19 |
2020-11-26 |
Synthena Ag |
Tricyclo-dna nucleoside precursors and processes for preparing the same
|
WO2019147743A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
EP3749767A1
(de)
|
2018-02-05 |
2020-12-16 |
Vertex Pharmaceuticals Incorporated |
Materialien und verfahren zur behandlung von hämoglobinopathien
|
MA51788A
(fr)
|
2018-02-05 |
2020-12-16 |
Vertex Pharma |
Substances et méthodes pour traiter des hémoglobinopathies
|
AU2019218987A1
(en)
|
2018-02-12 |
2020-07-23 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
AU2019218557A1
(en)
|
2018-02-12 |
2020-08-20 |
Interna Technologies B.V. |
Anticancer microRNA and lipid formulations thereof
|
US20210130824A1
(en)
|
2018-02-16 |
2021-05-06 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing by targeting fibrinogen-alpha
|
WO2019165453A1
(en)
|
2018-02-26 |
2019-08-29 |
Synthorx, Inc. |
Il-15 conjugates and uses thereof
|
EP3759127A4
(de)
|
2018-03-02 |
2022-03-30 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur modulation des amyloid-beta-vorläuferproteins
|
TW202000199A
(zh)
|
2018-03-02 |
2020-01-01 |
美商Ionis製藥公司 |
Irf4 表現之調節劑
|
AU2019239957A1
(en)
|
2018-03-19 |
2020-09-10 |
Bayer Healthcare Llc |
Novel RNA-programmable endonuclease systems and uses thereof
|
US11661601B2
(en)
|
2018-03-22 |
2023-05-30 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating FMR1 expression
|
US20210147847A1
(en)
|
2018-03-30 |
2021-05-20 |
Rheinische Friedrich-Wilhelms-Universitat Bonn |
Aptamers for targeted activaton of t cell-mediated immunity
|
WO2019195738A1
(en)
|
2018-04-06 |
2019-10-10 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
CA3094020A1
(en)
|
2018-04-11 |
2019-10-17 |
Ionis Pharmaceuticals, Inc. |
Modulators of ezh2 expression
|
WO2019204668A1
(en)
|
2018-04-18 |
2019-10-24 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
|
EP3788366B1
(de)
|
2018-05-03 |
2023-05-17 |
The Trustees of Wheaton College |
Verbesserte membranen für detektionsanwendungen mit nanoporen
|
SG11202010012PA
(en)
|
2018-05-09 |
2020-11-27 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing fxi expression
|
CA3098144A1
(en)
|
2018-05-09 |
2019-11-14 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing atxn3 expression
|
TW202016304A
(zh)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
CA3103429A1
(en)
|
2018-06-14 |
2019-12-19 |
Don W. Cleveland |
Compounds and methods for increasing stmn2 expression
|
MX2020013653A
(es)
|
2018-06-27 |
2021-03-02 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para la reduccion de la expresion de lrrk2.
|
TW202020154A
(zh)
|
2018-07-25 |
2020-06-01 |
美商Ionis製藥公司 |
用於減少atxn2表現之化合物及方法
|
AR114551A1
(es)
|
2018-08-13 |
2020-09-16 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE AGENTES DE ARNhd CONTRA EL VIRUS DE HEPATITIS B (HBV) Y MÉTODOS PARA SU USO
|
US20210348162A1
(en)
|
2018-08-16 |
2021-11-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
US11939582B2
(en)
|
2018-08-20 |
2024-03-26 |
Rogcon, Inc. |
Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies
|
WO2020047229A1
(en)
|
2018-08-29 |
2020-03-05 |
University Of Massachusetts |
Inhibition of protein kinases to treat friedreich ataxia
|
EP3620520A1
(de)
|
2018-09-10 |
2020-03-11 |
Universidad del Pais Vasco |
Neuartiges target zur behandlung einer stoffwechselerkrankung in einem individuum
|
AU2019339509A1
(en)
|
2018-09-14 |
2021-05-13 |
Northwestern University |
Programming protein polymerization with DNA
|
AU2019344776A1
(en)
|
2018-09-18 |
2021-01-21 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
|
TW202023573A
(zh)
|
2018-09-19 |
2020-07-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
US20210348159A1
(en)
|
2018-10-17 |
2021-11-11 |
Crispr Therapeutics Ag |
Compositions and methods for delivering transgenes
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
US11208650B2
(en)
|
2018-11-15 |
2021-12-28 |
Ionis Pharmaceuticals, Inc. |
Modulators of IRF5 expression
|
CA3117694A1
(en)
|
2018-11-21 |
2020-05-28 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing prion expression
|
US20210332495A1
(en)
|
2018-12-06 |
2021-10-28 |
Northwestern University |
Protein Crystal Engineering Through DNA Hybridization Interactions
|
CA3122402A1
(en)
|
2018-12-20 |
2020-06-25 |
Vir Biotechnology, Inc. |
Combination hbv therapy
|
US20220056455A1
(en)
|
2018-12-20 |
2022-02-24 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of kcnt1 related disorders
|
AU2019406214A1
(en)
|
2018-12-21 |
2021-08-05 |
Northwestern University |
Use of annexins in preventing and treating muscle membrane injury
|
WO2020139977A1
(en)
|
2018-12-26 |
2020-07-02 |
Northwestern University |
Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
|
MX2021008628A
(es)
|
2019-01-16 |
2021-11-17 |
Genzyme Corp |
Composiciones de arni para serpinc1 y metodos de uso de las mismas.
|
SG11202107399WA
(en)
|
2019-01-31 |
2021-08-30 |
Ionis Pharmaceuticals Inc |
Modulators of yap1 expression
|
CN114949240A
(zh)
|
2019-02-06 |
2022-08-30 |
新索思股份有限公司 |
Il-2缀合物及其使用方法
|
MA54951A
(fr)
|
2019-02-15 |
2021-12-22 |
Bayer Healthcare Llc |
Édition de gène pour l'hémophilie a avec une expression de facteur viii améliorée
|
US11279932B2
(en)
|
2019-02-27 |
2022-03-22 |
Ionis Pharmaceuticals, Inc. |
Modulators of MALAT1 expression
|
US20220175956A1
(en)
|
2019-03-06 |
2022-06-09 |
Northwestern University |
Hairpin-like oligonucleotide-conjugated spherical nucleic acid
|
WO2020185781A1
(en)
|
2019-03-11 |
2020-09-17 |
Ochsner Health System |
Microrna regulatory network as biomarkers of seizure in patients with spontaneous intracerebral hemorrhage
|
MA55297A
(fr)
|
2019-03-12 |
2022-01-19 |
Bayer Healthcare Llc |
Nouveaux systèmes d'endonucléase à arn programmable haute fidélité et leurs utilisations
|
SG11202110679YA
(en)
|
2019-03-29 |
2021-10-28 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating ube3a-ats
|
MX2021013698A
(es)
|
2019-05-13 |
2021-12-10 |
Vir Biotechnology Inc |
Composiciones y metodos para el tratamiento de la infeccion por virus de la hepatitis b (vhb).
|
EP3976791A4
(de)
|
2019-05-28 |
2023-10-11 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur verringerung der fus-expression
|
EP3976834A1
(de)
|
2019-05-31 |
2022-04-06 |
Streck, Inc. |
Nachweis von antibiotikaresistenzgenen
|
JP2022538784A
(ja)
|
2019-06-14 |
2022-09-06 |
ザ スクリプス リサーチ インスティテュート |
半合成生物における複製、転写および翻訳のための試薬ならびに方法
|
EP3956450A4
(de)
|
2019-07-26 |
2022-11-16 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur modulation von gfap
|
EP4007811A2
(de)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Carboxypeptidase-b2(cpb2)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP4007812A1
(de)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen der serpinfamilie f element 2 (serpinf2) und verfahren zu deren verwendung
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
EP4013454A1
(de)
|
2019-08-15 |
2022-06-22 |
Synthorx, Inc. |
Immunonkologische kombinationstherapien mit il-2-konjugaten
|
CN114555621A
(zh)
|
2019-08-15 |
2022-05-27 |
Ionis制药公司 |
键修饰的寡聚化合物及其用途
|
US20210054040A1
(en)
|
2019-08-23 |
2021-02-25 |
Synthorx, Inc. |
Novel il-15 conjugates and uses thereof
|
BR112022003860A2
(pt)
|
2019-09-03 |
2022-08-16 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para inibir a expressão do gene lect2
|
AU2020347154A1
(en)
|
2019-09-10 |
2022-03-03 |
Synthorx, Inc. |
IL-2 conjugates and methods of use to treat autoimmune diseases
|
US20220389429A1
(en)
|
2019-10-04 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
JP2022552249A
(ja)
|
2019-10-14 |
2022-12-15 |
アストラゼネカ・アクチエボラーグ |
Pnpla3発現のモジュレーター
|
WO2021076828A1
(en)
|
2019-10-18 |
2021-04-22 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
EP4048793A1
(de)
|
2019-10-22 |
2022-08-31 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c3 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
EP4052035A1
(de)
|
2019-10-31 |
2022-09-07 |
The Trustees of Wheaton College |
Entwurf und charakterisierung von mehrschichtigen strukturen zur unterstützung von lipiddoppelschichten
|
EP4051796A1
(de)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum unterdrücken der dnajb1-prkaca-fusionsgenexpression
|
CA3155921A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTINE (HTT) TARGETING RNAI AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
AU2020380275A1
(en)
|
2019-11-04 |
2022-04-14 |
Synthorx, Inc. |
Interleukin 10 conjugates and uses thereof
|
KR20220115946A
(ko)
|
2019-11-13 |
2022-08-19 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐 (agt) 관련 장애를 치료하기 위한 방법 및 조성물
|
WO2021102373A1
(en)
|
2019-11-22 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
AU2020391215A1
(en)
|
2019-11-27 |
2022-06-02 |
Bayer Healthcare Llc |
Methods of synthesizing RNA molecules
|
CN115151641A
(zh)
|
2019-12-13 |
2022-10-04 |
阿尔尼拉姆医药品有限公司 |
人类染色体9开放阅读框72(C9ORF72)iRNA剂组合物及其使用方法
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
WO2021122944A1
(en)
|
2019-12-18 |
2021-06-24 |
Alia Therapeutics Srl |
Compositions and methods for treating retinitis pigmentosa
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
US20230057461A1
(en)
|
2020-01-27 |
2023-02-23 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
BR112022015770A2
(pt)
|
2020-02-10 |
2022-10-11 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para silenciar a expressão de vegf-a
|
IL295496A
(en)
|
2020-02-18 |
2022-10-01 |
Alnylam Pharmaceuticals Inc |
Apolipoprotein c3 (apoc3) irna preparations and methods of using them
|
BR112022017136A2
(pt)
|
2020-02-28 |
2022-10-11 |
Tallac Therapeutics Inc |
Conjugação mediada por transglutaminase
|
US20220064638A1
(en)
|
2020-02-28 |
2022-03-03 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating smn2
|
EP4114947A1
(de)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
|
JP2023516095A
(ja)
|
2020-03-06 |
2023-04-17 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ケトヘキソキナーゼ(KHK)iRNA組成物およびその使用方法
|
WO2021188611A1
(en)
|
2020-03-18 |
2021-09-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
TW202204615A
(zh)
|
2020-03-26 |
2022-02-01 |
美商阿尼拉製藥公司 |
冠狀病毒iRNA組成物及其使用方法
|
EP4127171A2
(de)
|
2020-03-30 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur ausschaltung der dnajc15-genexpression
|
TW202204618A
(zh)
|
2020-04-06 |
2022-02-01 |
美商艾爾妮蘭製藥公司 |
用於靜默myoc表現之組合物及方法
|
EP4133077A1
(de)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon
|
CA3179678A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021222065A1
(en)
|
2020-04-27 |
2021-11-04 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
|
JP2023523790A
(ja)
|
2020-04-30 |
2023-06-07 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
補体因子B(CFB)iRNA組成物およびその使用方法
|
CA3181546A1
(en)
|
2020-05-01 |
2021-11-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating atxn1
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
EP4150086A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von leucinreicher repeat-kinase 2 (lrrk2)
|
EP4150088A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von argininosuccinat-synthetase (ass1)
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
EP4150076A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von methyl-cpg-bindendem protein 2 (mecp2)
|
EP4150090A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von otoflin (otof)
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
EP4153746A1
(de)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
EP4162050A1
(de)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
|
JP2023530461A
(ja)
|
2020-06-18 |
2023-07-18 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
キサンチンデヒドロゲナーゼ(XDH)iRNA組成物およびその使用方法
|
WO2021262840A1
(en)
|
2020-06-24 |
2021-12-30 |
Vir Biotechnology, Inc. |
Engineered hepatitis b virus neutralizing antibodies and uses thereof
|
CA3183834A1
(en)
|
2020-06-25 |
2021-12-30 |
Giovanni Abbadessa |
Immuno oncology combination therapy with il-2 conjugates and anti-egfr antibodies
|
MX2022016338A
(es)
|
2020-06-29 |
2023-01-24 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular la plp1.
|
TW202227102A
(zh)
|
2020-09-22 |
2022-07-16 |
瑞典商阿斯特捷利康公司 |
治療脂肪肝病之方法
|
EP4217489A1
(de)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022070107A1
(en)
|
2020-09-30 |
2022-04-07 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis
|
EP3978608A1
(de)
|
2020-10-05 |
2022-04-06 |
SQY Therapeutics |
Oligomere verbindung zur dystrophinrettung in dmd-patienten während des skipping exon-51
|
WO2022076291A1
(en)
|
2020-10-05 |
2022-04-14 |
Alnylam Pharmaceuticals, Inc. |
G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
|
WO2022076859A1
(en)
|
2020-10-09 |
2022-04-14 |
Synthorx, Inc. |
Immuno oncology therapies with il-2 conjugates
|
BR112023006364A2
(pt)
|
2020-10-09 |
2023-05-09 |
Synthorx Inc |
Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe
|
AU2021365822A1
(en)
|
2020-10-21 |
2023-06-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
EP4232582A1
(de)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
|
IL302709A
(en)
|
2020-11-13 |
2023-07-01 |
Alnylam Pharmaceuticals Inc |
Coagulation factor iRNA compositions (F5) and methods of using them
|
US11447521B2
(en)
|
2020-11-18 |
2022-09-20 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
US20240002853A1
(en)
|
2020-11-23 |
2024-01-04 |
Alpha Anomeric Sas |
Nucleic acid duplexes
|
WO2022119873A1
(en)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
EP4259795A1
(de)
|
2020-12-08 |
2023-10-18 |
Alnylam Pharmaceuticals, Inc. |
Gerinnungsfaktor x (f10)-irna-zusammensetzungen und verfahren zur verwendung davon
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
KR20220091160A
(ko)
|
2020-12-23 |
2022-06-30 |
삼성전자주식회사 |
증강 현실 디바이스 및 그 동작 방법
|
EP4267732A1
(de)
|
2020-12-23 |
2023-11-01 |
Flagship Pioneering Innovations VI, LLC |
Zusammensetzungen aus modifizierten tremen und verwendungen davon
|
WO2022150260A1
(en)
|
2021-01-05 |
2022-07-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
EP4291243A1
(de)
|
2021-02-12 |
2023-12-20 |
Synthorx, Inc. |
Lungenkrebskombinationstherapie mit il-2-konjugaten und einem anti-pd-1-antikörper oder antigenbindendem fragment davon
|
TW202305131A
(zh)
|
2021-02-12 |
2023-02-01 |
美商艾拉倫製藥股份有限公司 |
用於治療或預防超氧歧化酶1-(SOD1-)相關的神經退化疾病的超氧歧化酶1(SOD1)iRNA組成物及其使用方法
|
WO2022174101A1
(en)
|
2021-02-12 |
2022-08-18 |
Synthorx, Inc. |
Skin cancer combination therapy with il-2 conjugates and cemiplimab
|
JP2024509783A
(ja)
|
2021-02-25 |
2024-03-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
プリオンタンパク質(prnp)irna組成物およびその使用方法
|
BR112023016645A2
(pt)
|
2021-02-26 |
2023-11-14 |
Alnylam Pharmaceuticals Inc |
Composições de irna de ceto-hexoquinase (khk) e métodos de uso das mesmas
|
TW202302849A
(zh)
|
2021-03-04 |
2023-01-16 |
美商艾拉倫製藥股份有限公司 |
類血管生成素3(ANGPTL3)iRNA組成物及其使用方法
|
EP4305169A1
(de)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
|
US20220288181A1
(en)
|
2021-03-12 |
2022-09-15 |
Northwestern University |
Antiviral vaccines using spherical nucleic acids
|
AR125230A1
(es)
|
2021-03-29 |
2023-06-28 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE AGENTES DE ARNi CONTRA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO
|
EP4314293A1
(de)
|
2021-04-01 |
2024-02-07 |
Alnylam Pharmaceuticals, Inc. |
Prolindehydrogenase 2 (prodh2)-irna-zusammensetzungen und verfahren zur verwendung davon
|
TW202309291A
(zh)
|
2021-04-07 |
2023-03-01 |
法商新植物Sas公司 |
用於室內空氣修復之組合物及方法
|
TW202309280A
(zh)
|
2021-04-26 |
2023-03-01 |
美商艾拉倫製藥股份有限公司 |
跨膜絲胺酸蛋白酶6(TMPRSS6)iRNA組成物及其使用方法
|
EP4330396A1
(de)
|
2021-04-29 |
2024-03-06 |
Alnylam Pharmaceuticals, Inc. |
Signalwandler und aktivator von transkriptionsfaktor 6 (stat6)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP4334448A1
(de)
|
2021-05-03 |
2024-03-13 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von transthyretin(ttr)-vermittelter amyloidose
|
EP4341401A1
(de)
|
2021-05-18 |
2024-03-27 |
Alnylam Pharmaceuticals, Inc. |
Natriumglucose-cotransporter-2-(sglt2)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022246023A1
(en)
|
2021-05-20 |
2022-11-24 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
WO2022256395A1
(en)
|
2021-06-02 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
WO2022256538A1
(en)
|
2021-06-03 |
2022-12-08 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
|
US20220403450A1
(en)
|
2021-06-03 |
2022-12-22 |
Illumina Software, Inc. |
Systems and methods for sequencing nucleotides using two optical channels
|
AU2022283796A1
(en)
|
2021-06-04 |
2023-11-09 |
Alnylam Pharmaceuticals, Inc. |
HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
AR126070A1
(es)
|
2021-06-08 |
2023-09-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
|
EP4101928A1
(de)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Programmierbare typ-v-rna-endonukleasesysteme
|
CA3222950A1
(en)
|
2021-06-11 |
2022-12-15 |
Bayer Aktiengesellschaft |
Type v rna programmable endonuclease systems
|
EP4355759A1
(de)
|
2021-06-18 |
2024-04-24 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur reduzierung der ifnar1-expression
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
KR20240026203A
(ko)
|
2021-06-30 |
2024-02-27 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐(agt)-관련 장애를 치료하는 방법 및 조성물
|
CA3223131A1
(en)
|
2021-07-01 |
2023-01-05 |
Rean Silke MUSA |
Device having horizontal nanochannel for nanopore sequencing
|
WO2023285431A1
(en)
|
2021-07-12 |
2023-01-19 |
Alia Therapeutics Srl |
Compositions and methods for allele specific treatment of retinitis pigmentosa
|
WO2023003995A1
(en)
|
2021-07-23 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
WO2023009687A1
(en)
|
2021-07-29 |
2023-02-02 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
TW202328445A
(zh)
|
2021-08-03 |
2023-07-16 |
美商艾拉倫製藥股份有限公司 |
甲狀腺素運載蛋白(TTR)iRNA組成物及其使用方法
|
CA3228255A1
(en)
|
2021-08-04 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing angiotensinogen (agt)
|
AU2022328347A1
(en)
|
2021-08-13 |
2024-02-08 |
Alnylam Pharmaceuticals, Inc. |
Factor xii (f12) irna compositions and methods of use thereof
|
US11833221B2
(en)
|
2021-09-01 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds for reducing DMPK expression
|
CN117580961A
(zh)
|
2021-09-01 |
2024-02-20 |
Illumina公司 |
用于加速碱基判读的幅度调制
|
EP4144841A1
(de)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
AU2022345881A1
(en)
|
2021-09-20 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
US20230090867A1
(en)
|
2021-09-22 |
2023-03-23 |
Illumina, Inc. |
Sequencing polynucleotides using nanopores
|
WO2023056329A1
(en)
|
2021-09-30 |
2023-04-06 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
US20230112203A1
(en)
|
2021-09-30 |
2023-04-13 |
Illumina, Inc. |
Isolation of cells in a nanopore sensor array
|
CA3234835A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
CA3234636A1
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
WO2023076450A2
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2023086295A2
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Antisense oligonucleotides for modifying protein expression
|
WO2023086292A2
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Gata4-targeted therapeutics for treatment of cardiac hypertrophy
|
WO2023086391A1
(en)
|
2021-11-15 |
2023-05-19 |
Illumina, Inc. |
Nanopore systems and methods of fabrication
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
WO2023118349A1
(en)
|
2021-12-21 |
2023-06-29 |
Alia Therapeutics Srl |
Type ii cas proteins and applications thereof
|
WO2023122750A1
(en)
|
2021-12-23 |
2023-06-29 |
Synthorx, Inc. |
Cancer combination therapy with il-2 conjugates and cetuximab
|
WO2023118068A1
(en)
|
2021-12-23 |
2023-06-29 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023175018A1
(en)
|
2022-03-15 |
2023-09-21 |
Illumina, Inc. |
Concurrent sequencing of forward and reverse complement strands on separate polynucleotides
|
WO2023194359A1
(en)
|
2022-04-04 |
2023-10-12 |
Alia Therapeutics Srl |
Compositions and methods for treatment of usher syndrome type 2a
|
US20230357307A1
(en)
|
2022-05-04 |
2023-11-09 |
Illumina, Inc. |
Cleavable cyclic loop nucleotides for nanopore sequencing
|
WO2023237587A1
(en)
|
2022-06-10 |
2023-12-14 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2024010809A2
(en)
|
2022-07-07 |
2024-01-11 |
Illumina Software, Inc. |
Methods and systems for detecting recombination events
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
WO2024050261A1
(en)
|
2022-08-29 |
2024-03-07 |
University Of Rochester |
Antisense oligonucleotide-based anti-fibrotic therapeutics
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024056880A2
(en)
|
2022-09-16 |
2024-03-21 |
Alia Therapeutics Srl |
Enqp type ii cas proteins and applications thereof
|
WO2024073278A1
(en)
|
2022-09-26 |
2024-04-04 |
Illumina, Inc. |
Detecting and genotyping variable number tandem repeats
|
WO2024072685A1
(en)
|
2022-09-28 |
2024-04-04 |
Illumina, Inc. |
Fast pulsing for nanopore sensors
|